HRP20150837T1 - Heteroaril supstituirani pirolo[2,3-b]piridini i pirolo[2,3-b]pirimidini kao inhibitori janus kinaze - Google Patents

Heteroaril supstituirani pirolo[2,3-b]piridini i pirolo[2,3-b]pirimidini kao inhibitori janus kinaze Download PDF

Info

Publication number
HRP20150837T1
HRP20150837T1 HRP20150837TT HRP20150837T HRP20150837T1 HR P20150837 T1 HRP20150837 T1 HR P20150837T1 HR P20150837T T HRP20150837T T HR P20150837TT HR P20150837 T HRP20150837 T HR P20150837T HR P20150837 T1 HRP20150837 T1 HR P20150837T1
Authority
HR
Croatia
Prior art keywords
pyrazol
pyrrolo
pyrimidin
propanenitrile
phenyl
Prior art date
Application number
HRP20150837TT
Other languages
English (en)
Inventor
James D. Rodgers
Stacey Shepard
Thomas P. Maduskuie
Haisheng Wang
Nikoo Falahatpisheh
Maria Rafalski
Argyrios G. Arvantis
Louis Storace
Ravi Kumar Jalluri
Jordan S. Fridman
Krishna Vaddi
Original Assignee
Incyte Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37903501&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20150837(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Incyte Corporation filed Critical Incyte Corporation
Publication of HRP20150837T1 publication Critical patent/HRP20150837T1/hr
Publication of HRP20150837T2 publication Critical patent/HRP20150837T2/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (38)

1. Farmaceutski sastav koji sadrži spoj formule: [image] ili njegovu farmaceutski prihvatljivu sol, pri čemu: T, U i V su nezavisno izabrani od O, S, N, CR5, i NR6; pri čemu je 5-člani prsten formiran od atoma ugljika, atoma dušika, U, T i V aromatičan; X je N ili CR4; n je 0; ili n je 1 i Y je C1-8 alkilen, C2-8 alkenilen, (CR11R12)pC(O)(CR11R12)q, (CR11R12)pC(O)NRc(CR11R12)q, (CR11R12)pC(O)O(CR11R12)q, ili (CR11R12)pOC(O)(CR11R12)q, pri čemu je navedeni C1-8 alkilen ili C2-8 alkenilen, opcionalno supstituiran s 1, 2 ili 3 halo, OH, CN, amino, C1-4 alkilamino ili C2-8 dialkilamino; Z je aril, cikloalkil, heteroaril ili heterocikloalkil, svaki opcionalno supstituiran s 1, 2, 3, 4, 5 ili 6 supstituenata neovisno izabranih od halo, C1-4 alkila, C2-4 alkenila, C2-4 alkinila, C1-4 haloalkila, C1-4 hidroksialkila, C1-4 cijanoalkila, Cy1, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rb, NRcC(O)NRcRd, NRcC(O)ORa, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb i S(O)2NRcRd; Cy1 je neovisno izabran od arila, heteroarila, cikloalkila i heterocikloalkila, svaki opcionalno supstituiran s 1, 2, 3, 4 ili 5 supstituenata neovisno izabranih od halo, C1-4 alkila, C2-4 alkenila, C2-4 alkinila, C1-4 haloalkila, CN, NO2, ORa", SRa", C(O)Rb", C(O)NRc"Rd", C(O)ORa", OC(O)Rb", OC(O)NRc"Rd", NRc"Rd", NRc"C(O)Rb", NRc"C(O)ORa" S(O)Rb", S(O)NRc"Rd", S(O)2Rb" i S(O)2NRc"Rd"; R4 je H; R5 je H, halo, C1-4 alkil, C2-4 alkenil, C2-4 alkinil, C1-4 haloalkil, CN, NO2, OR7, SR7, C(O)R8, C(O)NR9R10, C(O)OR7,OC(O)R8, OC(O)NR9R10, NR9R10, NR9C(O)R8, NR9C(O)OR7, S(O)R8, S(O)NR9R10 S(O)2R8, NR9S(O)2R8 ili S(O)2NR9R10; R6 je H, C1-4 alkil, C2-4 alkenil, C2-4 alkinil, C1-4 haloalkil, OR7, C(O)R8, C(O)NR9R10, C(O)OR7, S(O)R8, S(O)NR9R10, S(O)2R8, ili S(O)2NR9R10; R7 je H, C1-6 alkil, C1-6 haloalkil, C2-6alkenil, C2-6alkinil, aril, cikloalkil, heteroaril, heterocikloalkil, arilalkil, heteroarilalkil, cikloalkilalkil ili heterocikloalkilalkil; R8 je H, C1-6 alkil, C1-6 haloalkil, C2-6 alkenil, C2-6 alkinil, aril, cikloalkil, heteroaril, heterocikloalkil, arilalkil, heteroarilalkil, cikloalkilalkil ili heterocikloalkilalkil; R9 i R10 su neovisno izabrani od H, C1-10 alkila, C1-6 haloalkila, C2-6 alkenila, C2-6 alkinila, C1-6 alkilkarbonila, arilkarbonila, C1-6 alkilsulfonila, arilsulfonila, arila, heteroarila, cikloalkila, heterocikloalkila, arilalkila, heteroarilalkila, cikloalkilalkila i heterocikloalkilalkila; ili R9 i R10 zajedno s atomom dušika na koji su spojeni čine 4-, 5-, 6- ili 7-članu heterocikloalkil skupinu; R11 i R12 su neovisno izabrani od H, halo, OH, CN, C1-4 alkila, C1-4 haloalkila, C2-4 alkenila, C2-4 alkinila, C1-4 hidroksialkila, C1-4 cijanoalkila, arila, heteroarila, cikloalkila, i heterocikloalkila; Ra i Ra" su neovisno izabrani od H, C1-6 alkila, C1-6 haloalkila, C2-6 alkenila, C2-6 alkinila, arila, cikloalkila, heteroarila, heterocikloalkila, arilalkila, heteroarilalkila, cikloalkilalkila i heterocikloalkilalkila, pri čemu je navedeni C1-6 alkil, C1-6 haloalkil, C2-6 alkenil, C2-6 alkinil, aril, cikloalkil, heteroaril, heterocikloalkil, arilalkil, heteroarilalkil, cikloalkilalkil ili heterocikloalkilalkil opcionalno supstituiran s 1, 2 ili 3 supstituenta neovisno izabrana od OH, CN, amino, halo, C1-6 alkila, C1-6 haloalkila, arila, arilalkila, heteroarila, heteroarilalkila, cikloalkila i heterocikloalkila; Rb i Rb" su neovisno izabrani od H, C1-6 alkila, C1-6 haloalkila, C2-6 alkenila, C2-6 alkinila, arila, cikloalkila, heteroarila, heterocikloalkila, arilalkila, heteroarilalkila, cikloalkilalkila i heterocikloalkilalkila, pri čemu je navedeni C1-6 alkil, C1-6 haloalkil, C2-6 alkenil, C2-6 alkinil, aril, cikloalkil, heteroaril, heterocikloalkil, arilalkil, heteroarilalkil, cikloalkilalkil ili heterocikloalkilalkil opcionalno supstituiran s 1, 2 ili 3 supstituenta neovisno izabranih od OH, CN, amino, halo, C1-6 alkila, C1-6 haloalkila, C1-6 haloalkila, arila, arilalkila, heteroarila, heteroarilalkila, cikloalkila i heterocikloalkila; Rc i Rd su neovisno izabrani od H, C1-10 alkila, C1-6 haloalkila, C2-6 alkenila, C2-6 alkinila, arila, heteroarila, cikloalkila, heterocikloalkila, arilalkila, heteroarilalkila, cikloalkilalkila i heterocikloalkilalkila, pri čemu je navedeni C1-10 alkil, C1-6 haloalkil, C2-6 alkenil, C2-6 alkinil, aril, heteroaril, cikloalkil, heterocikloalkil, arilalkil, heteroarilalkil, cikloalkilalkil ili heterocikloalkilalkil opcionalno supstituiran s 1, 2 ili 3 supstituenta neovisno izabranih od OH, CN, amino, halo, C1-6 alkila, C1-6 haloalkila, C1-6 haloalkila, arila, arilalkila, heteroarila, heteroarilalkila, cikloalkila ili heterocikloalkila; ili Rc i Rd zajedno s atomom dušika na koji su spojeni čine 4-, 5-, 6- ili 7-članu heterocikloalkil skupinu opcionalno supstituiranu s 1, 2 ili 3 supstituenta neovisno izabrana od OH, CN, amino, halo, C1-6alkila, C1-6haloalkila, C1-6 haloalkila, arila, arilalkila, heteroarila, heteroarilalkila, cikloalkila i heterocikloalkila; Rc" i Rd" su neovisno izabrani od H, C1-10 alkila, C1-6 haloalkila, C2-6 alkenila, C2-6 alkinila, arila, heteroarila, cikloalkila, heterocikloalkila, arilalkila, heteroarilalkila, cikloalkilalkila i heterocikloalkilalkila, pri čemu je navedeni C1-10 alkil, C1-6 haloalkil, C2-6 alkenil, C2-6 alkinil, aril, heteroaril, cikloalkil, heterocikloalkil, arilalkil, heteroarilalkil, cikloalkilalkil ili heterocikloalkilalkil opcionalno supstituiran s 1, 2 ili 3 supstituenta neovisno izabrana od OH, CN, amino, halo, C1-6 alkila, C1-6 haloalkila, C1-6 haloalkila, arila, arilalkila, heteroarila, heteroarilalkila, cikloalkila i heterocikloalkila; ili Rc" i Rd" zajedno s atomom dušika na koji su spojeni čine 4-, 5-, 6- ili 7-članu heterocikloalkil skupinu opcionalno supstituiranu s 1, 2, ili 3 supstituenta neovisno izabrana od OH, CN, amino, halo, C1-6 alkila, C1-6 haloalkila, C1-6 haloalkila, arila, arilalkila, heteroarila, heteroarilalkila, cikloalkila i heterocikloalkila; p je 0, 1, 2, 3, 4, 5 ili 6; i q je 0, 1, 2, 3, 4, 5 ili 6. i farmaceutski prihvatljiv nosač; pri čemu je navedeni sastav pogodan za oralnu primjenu i za osiguravanje produženog oslobađanja navedenog spoja ili navedene soli.
2. Farmaceutski sastav prema zahtjevu 1, pri čemu je spoj spoj Formule II: [image] ili njegova farmaceutski prihvatljiva sol.
3. Farmaceutski sastav prema zahtjevu 1 ili 2, pri čemu X je N.
4. Farmaceutski sastav prema bilo kojem od patentnih zahtjeva 1 do 3, pri čemu n je 0.
5. Farmaceutski sastav prema bilo kojem od patentnih zahtjeva 1 do 3, pri čemu n je 1 i Y je C1-8 alkilen opcionalno supstituiran s 1, 2 ili 3 halo, OH, CN, amino, C1-4 alkilamino, ili C2-8 dialkilamino.
6. Farmaceutski sastav prema bilo kojem od patentnih zahtjeva 1 do 5, pri čemu Z je cikloalkil, opcionalno supstituiran s 1, 2, 3, 4, 5 ili 6 supstituenata neovisno izabranih od halo, C1-4 alkila, C2-4 alkenila, C2-4 alkinila, C1-4 haloalkila, C1-4 hidroksialkila, C1-4 cijanoalkila, Cy1, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd, NRcRd, NR cC(O)Rb, NRcC(O)NRcRd, NRcC(O)ORa, S(O)Rb, S(§O)NRcRd, S(O)2Rb, NRcS(O)2Rb, i S(O)2NRcRd.
7. Farmaceutski sastav prema bilo kojem od patentnih zahtjeva 1 do 5, pri čemu Z je heterocikloalkil, opcionalno supstituiran s 1, 2, 3, 4, 5 ili 6 supstituenata neovisno izabranih od halo, C1-4 alkila, C2-4 alkenila, C2-4 alkinila, C1-4 haloalkila, C1-4 hidroksialkila, C1-4 cijanoalkila, Cy1, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rb, NRcC(O)NRcRd, NRcC(O)ORa, S(O)Rb, S(O)NcRd, S(O)2Rb, NRcS(O)2Rb, i S(O)2NRcRd.
8. Farmaceutski sastav prema zahtjevu 1, pri čemu je navedeni spoj izabran od: 4-[1-(1-metil-3-pirazol-1-il-propil)-1H-pirazol-4-il]-1H-pirolo[2,3-b]piridina; 4-[1-(3-imidazol-1-il-1-metil-propil)-1H-pirazol-4-il]-1H-pirolo[2,3-b]piridina; 4-ciklopentil-4-[4-(1H-pirolo[2,3-b]piridin-4-il)-pirazol-1-il]-butironitrila; 3-ciklopropil-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-pirazol-1-il]-propionitrila; 3-ciklopentil-3-[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]propannitrila; 3-cikloheksil-3-[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]propannitrila; 3-ciklopentil-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 3-cikloheksil-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 3-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]ciklopropilpropannitrila; 4-ciklopropil-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]butanonitrila; 1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]ciklopropilacetonitrila; 4-1-[(pirolidin-2-il)metil]-1H-pirazol-4-il-7H-pirolo[2,3-d]pirimidina; 4-(1-[1-(metilsulfonil)pirolidin-2-il]metil-1H-pirazol-4-il)-7H-pirolo[2,3-d]pirimidina; 3-ciklopentil-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]akrilonitrila; 3-(2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil)-ciklopentan-karbonitrila; 3-[3-(hidroksimetil)ciklopentil]-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-propannitrila; 4-(1-benzil-1H-pirazol-4-il)-1H-pirolo[2,3-b]piridina; 4-[1-(2-naftilmetil)-1H-pirazol-4-il]-1H-pirolo[2,3-b]piridina; 4-(1-fenil-1H-pirazol-4-il)-1H-pirolo[2,3-b]piridina; 3-[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]benzonitrila; 4-metil-3-[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]benzonitrila; 4-[1-(3,5-dimetoksibenzil)-1H-pirazol-4-il]-1H-pirolo[2,3-b]piridina; 4-[1-(1-feniletil)-1H-pirazol-4-il]-1H-pirolo[2,3-b]piridina; 4-[1-(cikloheksilmetil)-1H-pirazol-4-il]-1H-pirolo[2,3-b]piridina; 3-{[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]metil}benzonitrila; 2-{[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]metil}benzonitrila; 4-{[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]metil}benzonitrila; 1-fenil-2-[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]etanona; 4-{1-[(5-metilizoksazol-3-il)metil]-1H-pirazol-4-il}-1H-pirolo[2,3-b]piridina; 4-[1-(tetrahidro-2H-piran-2-ilmetil)-1H-pirazol-4-il]-1H-pirolo[2,3-b]piridina; 4-(1-cikloheks-2-en-1-il-1H-pirazol-4-il)-1H-pirolo[2,3-b]piridina; 4-(1-cikloheksil-1H-pirazol-4-il)-1H-pirolo [2,3-b]piridina; 4’-{[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]metil}bifenil-2-karbonitrila; 4-[1-(2-nitrobenzil)-1H-pirazol-4-il]-1H-pirolo[2,3-b]piridina; 4-{1-[2,6-dikloro-4-(trifluorometil)fenil]-1H-pirazol-4-il}-1H-pirolo[2,3-b]piridina; 4-[1-(3-nitrobenzil)-1H-pirazol-4-il]-1H-pirolo[2,3-b]piridina; 4-[1-(2-bromobenzil)-1H-pirazol-4-il]-1H-pirolo[2,3-b]piridina; N-fenil-2-[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]propanamida; 4-{1-[3-(trifluorometoksi)benzil]-1H-pirazol-4-il}-1H-pirolo[2,3-b]piridina; 4-{1-[2-fluoro-5-(trifluorometil)benzil]-1H-pirazol-4-il}-1H-pirolo[2,3-b]piridina; 4-{1-[3-(trifluorometil)benzil]-1H-pirazol-4-il}-1H-pirolo[2,3-b]piridina; 4-[1-(piridin-3-ilmetil)-1H-pirazol-4-il]-1H-pirolo[2,3-b]piridina; 4-{1-[1-fenilbutil]-1H-pirazol-4-il}-1H-pirolo[2,3-b]piridina; 1-fenil-2-[4-(1H-pirolo[2,3-b]piridin-4-il)-H-pirazol-1-il]propan-1-ona; 4-[1-(2,6-diklorobenzil)-1H-pirazol-4-il]-1H-pirolo[2,3-b]piridina; 4-[1-(2,6-dimetilfenil)-1H-pirazol-4-il]-1H-pirolo[2,3-b]piridina; 2-[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]-5-(trifluorometil)-benzonitrila; 4-[1-(4-bromo-3,5,6-trifluoropiridin-2-il)-1H-pirazol-4-il]-1H-pirolo[2,3-b]piridina; 4-[1-(ciklopropilmetil)-1H-pirazol-4-il]-1H-pirolo[2,3-b]piridina; 4-[1-(2,5-dimetilfenil)-1H-pirazol-4-il]-1H-pirolo[2,3 -b]piridina; 4-[1-(2-metilfenil)-1H-pirazol-4-il]-1H-pirolo[2,3-b]piridina; 4-[1-(2-metoksifenil)-1H-pirazol-4-il]-1H-pirolo[2,3-b]piridina; 3-{1-[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]etil} benzonitrila; 3-kloro-4-[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]benzonitrila; 4-[1-(1-cikloheksiletil)-1H-pirazol-4-il]-1H-pirolo[2,3-b]piridina; 4-fluoro-2-[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]benzonitrila; 2-fluoro-4-[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]benzonitrila; 3-fluoro-4-[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]benzonitrila; 4-(1-{1-[3-(trifluorometil)fenil]etil}-1H-pirazol-4-il)-1H-pirolo[2,3-b]piridina; 4-[1-(3,5-dimetilfenil)-1H-pirazol-4-il]-H-pirolo[2,3-b]piridina; 4-[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]benzonitrila; {4-[4-(1 H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]fenil}acetonitrila; 4-[1-( -fenilpropil)-1H-pirazol-4-il]-1H-pirolo[2,3-b]piridina; 4-(1-{1-[4-(metilsulfonil)fenil]etil}-1H-pirazol-4-il)-1H-pirolo[2,3-b]piridina; 4-{1-[ 1-(3-fluoro-4-metoksifenil)etil]-1H-pirazol-4-il}-1H-pirolo[2,3-b]piridina; 4-(1-{11-[2-(trifluorometil)fenil]etil}-1H-pirazol-4-il)-1H-pirolo[2,3-b]piridina; 4-(1-{1-[3,5-bis(trifluorometil)fenil]etil}-1H-pirazol-4-il)-1H-pirolo[2,3-b]piridina; 4-{1-[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]etil} benzonitrila; 4-{1-[4-nitro-2-(trifluorometil)fenil]-1H-pirazol-4-il}-1H-pirolo[2,3-b]piridina; 3-metil-4-[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]benzonitrila; 4-[1-(2-klorofenil)-1H-pirazol-4-il]-1H-pirolo[2,3-b]piridina; 3-bromo-4-[4-(1 H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]benzonitrila; etil 4-[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]benzoata; 4-{1-[2-kloro-6-nitro-4-(trifluorometil)fenil]-1H-pirazol-4-il}-1H-pirolo[2,3-b]piridina; 4-(1-{1-[4-(trifluorometil)fenil]etil}-1H-pirazol-4-il)-1H-pirolo[2,3-b]piridina; 4-[1-(2,3-dihidro-1H-inden-1-il)-1H-pirazol-4-il]-1H-pirolo[2,3-b]piridina; 4-[1-(1,2,3,4-tetrahidronaftalen-1-il)-1H-pirazol-4-il]-1 H-pirolo [2,3-b]piridina; 4-(1-{1-[2-kloro-5-(trifluorometil)fenil]etil}-1H-pirazol-4-il)-1H-pirolo[2,3-b]piridina; 4-{1-[11-(2,4-dikloro-5-fluorofenil)etil]-1H-pirazol-4-il}-1H-pirolo[2,3-b]piridina; 4-[1-(1-ciklopentiletil)-1H-pirazol-4-il]-1H-pirolo[2,3-b]piridina; 4-[1-(1-metil-3-fenilpropil)-1H-pirazol-4-il]-1H-pirolo[2,3-b]piridina; 4-[1-(1-ciklobutiletil)-1H-pirazol-4-il]-1H-pirolo[2,3-b]piridina; [2-[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]-5-(trifluorometil)fenil]-acetonitrila; [5-[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]-2-(trifluorometil)fenil]-acetonitrila; 4-{1-[4-fenilbut-3-en-1-il]-1H-pirazol-4-il}-1H-pirolo[2,3-b]piridina; [3-kloro-2-[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]-5-(trifluorometil)fenil]-acetonitrila; 5-[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]-2-(trifluorometil)-benzonitrila; 4-{1-[2-kloro-4-(trifluorometil)fenil]-1H-pirazol-4-il}-1H-pirolo[2,3-b]piridina; 4-[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]-2-(trifluorometil)-benzonitrila; 2-[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]benzonitrila; 3-kloro-2-[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]benzonitrila; 4-amino-5,6-difluoro-2-[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]izoftalonitrila; 1-{[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]metil}-ciklopropankarbonitrila; 5-bromo-2-[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]benzonitrila; 3-[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]-4-(trifluorometil)-benzonitrila; 2-[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]-3-(trifluorometil)-benzonitrita; 3-[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]-4-(trifluorometil)benzamida; 3-[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]cikloheksanona; 2-[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1 -il]cikloheksanola; 4-(1-{[-(metilsulfonil)piperidin-4-il]metil}-1H-pirazol-4-il)-1H-pirolo[2,3-b]piridina; 2-[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]cikloheksankarbonitrila; 4-{1-[2-(trifluorometil)fenil]-1H-pirazol-4-il}-1H-pirolo[2,3-b]piridina; 4-[1-(2,6-diklorofenil)-1H-pirazol-4-il] -1 H-pirolo[2,3-b]piridina; (4-{[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]metil}cikloheksil)metanola; 4-[1-(tetrahidrofuran-2-ilmetil)-1H-pirazol-4-il]-1H-pirolo[2,3-b]piridina; 4-[1-(1-ciklopentilpropil)-1H-pirazol-4-il]-1H-pirolo[2,3-b]piridina; 4-[1-(tetrahidrofuran-3-ilmetil)-1H-pirazol-4-il]-1H-pirolo[2,3-b]piridina; 2-kloro-3-[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]benzonitrila; 3-[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]-3-(1,3-tiazol-5-il)propannitrila; 3-(1-metil-1H-imidazol-5-il)-3-[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il] propannitrila; 3-[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]-3-(3-tienil)propannitrila; {1-[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]ciklopentil}acetonitrila; 4-kloro-3-[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]benzonitrila; 4-[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]ftalonitrila; 3-metil-4-[4-(1H-pirolo[2,3-b]piridin-4-il)-1 H-pirazol-1-il]benzaldehida; 4-[1-(2-metil-4-nitrofenil)-1H-pirazol-4-il]-1H-pirolo[2,3-b]piridina; 3-[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]ciklopentanona; 4-[1-(3-furilmetil)-1H-pirazol-4-il]-1H-pirolo[2,3-b]piridina; 4-[1-(2-furilmetil)-1H-pirazol-4-il]-1H-pirolo[2,3-b]piridina; 3-{2-cijano-1-[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]etil}benzonitrila; {3-metil-4-[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]fenil} metanola; 3-(1-benzofuran-2-il)-3-[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]propannitrila; 3-(3-furil)-3-[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]propannitrila; {3-metil-4-[4-(1H-pirolo[2,3-b]piridin-4-il)-1H-pirazol-1-il]fenil} acetonitrila; 4-metil-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]benzonitrila; 4-[-(11-ciklopentilpropil)-1H-pirazol-4-il]-7H-pirolo[2,3-d]pirimidina; {1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]ciklopentil}acetonitrila; 3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}benzonitrila; 3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-3-(3-tienil)propannitrila; 4-kloro-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]benzonitrila; 3-(3-furil)-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 3-{1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]ciklopentil}-propannitrila; {1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]cikloheksil}acetonitrila; {3-metil-4-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]fenil}metanola; 3-piridin-4-il-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 3-piridin-3-il-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 3-[4-(metiltio)fenil]-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 3-(3-metoksifenil)-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 3-(4-metoksifenil)-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; {3-metil-4-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]fenil}acetonitrila; 3-[4-(metilsulfinil)fenil]-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-propannitrila; 3-[4-(metilsulfonil)fenil]-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-propannitrila; 3-[3-(cijanometoksi)fenil]-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1 H-pirazol-1-il]-propannitrila; 3-(6-kloropiridin-3-il)-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 5-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}piridin-2-karbonitrila; 3-(3,5-dimetilizoksazol-4-il)-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-propannitrila; 3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-3-[6-(trifluorometil)piridin-3-il]-propannitrila; 3-(6-metoksipiridin-3-il)-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 3-piridin-2-il-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 3-(6-bromopiridin-2-il)-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 6-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}piridin-2-karbonitrila; 3-(5-bromopiridin-3-il)-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 5-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}nikotinonitrila; 3-(2-metoksipiridin-3-il)-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 3-[4-(cijanometoksi)fenil]-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 3-[2-(cijanometoksi)fenil]-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-propannitrila; 3-(3,5-dibromofenil)-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 5-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}izoftalonitrila; 3-[6-(dimetilamino)piridin-2-il]-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-propannitrila; 3-(4-bromo-2-tienil)-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 5-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}tiofen-3-karbonitrila; 3-(5-bromo-2-fluorofenil)-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-propannitrila; 3-(3-nitrofenil)-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 3-(5-bromo-2-metoksifenil)-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-propannitrila; 3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}-4-metoksibenzo-nitrila; 3-(3-bromofenil)-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}-4-fluorobenzonitrila; 3-[5-bromo-2-(cijanometoksi)fenil]-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-propannitrila; 3-(4-bromo-2-furil)-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 4-(cijanometoksi)-3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}-benzonitrila; 3-(4-bromopiridin-2-il)-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 2-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}izonikotinonitrila; 5-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}-3-furonitrila; 3-[2-bromo-5-(cijanometoksi)fenil]-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-propannitrila; 4-(cijanometoksi)-2-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-etil benzonitrila; 3-pirimidin-5-il-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 3-(2-bromopiridin-4-il)-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 4-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}piridin-2-karbonitrila; 3-(5-metoksipiridin-3-il)-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 3-(3-klorofenil)-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-3-[3-(trifluorometil)fenil]-propannitrila; 3-(3-fenoksifenil)-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-3-[3-(trifluorometoksi)-fenil]-propannitrila; metil 3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}benzoata; 3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}benzojeve kiseline; 3-[3-(1H-pirazol-4-il)fenil]-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-propannitrila; 3-(3-aminofenil)-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; N-(3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}fenil)acetamida; N-(3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}fenil)-metansulfonamida; 4-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}tiofen-2-karbonitrila; 5-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}tiofen-2-karbonitrila; 3-[3-(morfolin-4-ilkarbonil)fenil]-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-propannitrila; N-(2-aminoetil)-3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}-benzamida; 3-(5-formil-3-tienil)-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}-N-metilbenzamida; 2-cijano-N-(3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}fenil)-acetamida; N-(3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}fenil)-nikotinamida; N-(3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}fenil)-N’-izopropilureje; izopropil (3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}fenil)-karbamata; 3 -(5 -fenilpiridin-3 -il)-3 -[4-(7H-pirolo [2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 3-(3,3’-bipiridin-5-il)-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 3-(5-pirimidin-5-ilpiridin-3-il)-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-propannitrila; 3-[5-(1-metil-1H-pirazol-4-il)piridin-3-il]-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 3-(5-etinilpiridin-3-il)-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 3-[5-(feniltio)piridin-3-il]-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-propannitrila; 3-(2-bromo-1,3-tiazol-5-il)-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-propannitrila; 3-(5-morfolin-4-ilpiridin-3-il)-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-propannitrila; 3-(1-metil-1H-pirazol-4-il)-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-propannitrila; 3-(3-piridin-3-ilfenil)-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 3-[5-(fenilsulfinil)piridin-3-il]-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-propannitrila; 3-[5-(fenilsulfonil)piridin-3-il]-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-propannitrila; 3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-3-[5-(1,3-tiazol-2-iltio)piridin-3-il]propannitrila; 3-[5-(etiltio)piridin-3-il]-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-propannitrila; 4-{1-[1-metil-2-(1H-1,2,4-triazol-1-il)etil]-1H-pirazol-4-il}-7H-pirolo[2,3-d]pirimidina; 1-fenil-2-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propan-1-ona; 3-[5-(etilsulfinil)piridin-3-il]-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-propannitrila; 3-[5-(etilsulfonil)piridin-3-il]-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-propannitrila; 3-[5-(cikloheksiltio)piridin-3-il]-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-propannitrila; 1-fenil-2-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propan-1-ola; 3-[3-(etiltio)fenil]-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 3-[3-(etilsulfinil)fenil]-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-propannitrila; 3-[3-(etilsulfonil)fenil]-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-propannitrila; 3-[5-(cikloheksilsulfonil)piridin-3-il]-3-[4-(7H-pirolo[2,3-d]¬pirimidin-4-il)-1H-pirazol-1-il] propannitrila; 3-[5-(cikloheksilsulfinil)piridin-3-il]-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 4-[1-(1-metil-2-feniletil)-1H-pirazol-4-il]-7H-pirolo[2,3-d]pirimidina; 4-{1-[1-metil-2-(3-tienil)etil]-1H-pirazol-4-il}-7H-pirolo[2,3-d]pirimidina; 3-{1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}benzonitrila; 4-{1-[2-(1H-imidazol-1-il)-1-metiletil]-1H-pirazol-4-il}-7H-pirolo[2,3-d]pirimidina; 4-{1-[1-metil-2-(3-metil-1,2,4-oksadiazol-5-il)etil]-1H-pirazol-4-il}-7H-pirolo[2,3-d]-pirimidina; 3-[3-(metilsulfonil)fenil]-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-propannitrila; 3-(3-piridin-4-ilfenil)-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 3-[5-(izopropiltio)piridin-3-il]-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-propannitrila; 3-[5-(izopropilsulfinil)piridin-3-il]-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 3-[5-(izopropilsulfonil)piridin-3-il]¬-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-l-il]-3-[5-(trifluorometil)piridin-3-il]-propannitrila; 2-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-N-[3-(trifluorometil)fenil]-propanamida; N-2-naftil-2-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propanamida; N-1-naftil-2-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propanamida; N-(3-cijanofenil)-2-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propanamida; N-fenil-2-[4-(7H-pirolo [2,3-d]¬pirimidin-4-il)-1H-pirazol-1-il]-butanamida; N-(4-fenoksifenil)-2-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]butanamida; N-2-naftil-2-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]butanamida; N-(3-cijanofenil)-2-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]butanamida; N-bifenil-4-il-2-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]butanamida; N-(bifenil-4-ilmetil)-2-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]butanamida; N-(bifenil-3-ilmetil)-2-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]butanamida; N-(4-cijanofenil)-2-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]butanamida; N-1-naftil-2-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]butanamida; 5-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}-N-fenilnikotinamida; N-(3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}fenil)-3-(trifluorometil)benzamida; N-(3-{[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]metil}fenil)-3-(trifluorometil)benzamida; 3-[3-(metilsulfonil)fenil]-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-propannitrila; N-(3-{[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]metil}fenil)benzen-sulfonamida; 3-{[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]metil}-N-[3-(trifluorometil)-fenil]benzamida; 3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}-N,N-dimetil-benzensulfonamida; N-benzil-3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}benzen-sulfonamida; N-benzil-3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}benzamida; 3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}-N-fenilbenzamida; 3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}-N-[3-(trifluoro-metil)fenil]benzamida; N-(3-cijanofenil)-3-{[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]metil}-benzamida; N-benzil-3-{[4-(7H-pirolo¬[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]metil}benzamida; N-1-naftil-3-{[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]metil}benzamida; N-2-naftil-3-{[4-(7H-pirolo[2,3-d]-pirimidin-4-il)-1H-pirazol-1-il]metil}benzamida; N-(3-{[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]metil}fenil)-2-naftamida; N-(3-{[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]metil}fenil)-1-naftamida; 2-fenil-N-(3-{[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]metil}fenil)-acetamida; 3-kloro-N-(3-{[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il] metil} fenil)-benzamida; N-(3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il] etil}fenil)-2-naftamida; N-(3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}fenil)-1-naftamida; N-(3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-etil}fenil)-2-fenilacetamida; 3-cijano-N-(3-{2-cijano-1-[4-(7 H-pirolo[2,3 -d]pirimidin-4-il)-1H-pirazol-1-il]etil}fenil)-benzamida; N-(3-{2-ciano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}fenil)-benzamida; N-(3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}fenil)-4-(trifluorometil)benzamida; N-(3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}fenil)-N’-fenilureje; 3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}-N-[4-(trifluoro-metil)fenil]benzamida; 3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}-N-(4-metilfenil)benzamida; N-(4-cijanofenil)-3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-etil} benzamida; 3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}-N-2-naftil-benzamida; 3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}-N-1-naftil-benzamida; 3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}-N,N-dimetil-benzamida; 3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}-N-piridin-3-il-benzamida; 3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}-N-metil-N-fenil-benzamida; 3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}-N-cikloheksil-benzamida; N-(3-cijanofenil)-3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}-benzamida; N-bifenil-4-il-3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-etil}benzamida; N-(4-klorofenil)-3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-etil}benzamida; 3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}-N-(3,4-dimetil-fenil)benzamida; 3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}-N-izoksazol-3-il-benzamida; 3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}-N-metil-N-fenilbenzensulfonamida; 3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}-N-propilbenzen-sulfonamida; 3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}-N-fenil-benzensulfonamida; 3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}-N-2-naftil-benzensulfonamida; 3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}-N-ciklopropil-benzensulfonamida; 3-[3-(piperidin-1-ilsulfonil)fenil]-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-propannitrila; 3-[3-(morfolin-4-ilsulfonil)fenil]-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-propannitrila; 3-{2-ciano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}-N-(4-metilfenil)-benzensulfonamida; 3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}-N-(3,4-dimetil-fenil)benzensulfonamida; 3-[3-(benzilsulfonil)fenil]-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-propannitrila; 3-[3-(benziltio)fenil]-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 4-{[(3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}fenil)-sulfonil]metil}benzonitrila; 3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}-N-metilbenzen-sulfonamida; 3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}-N-1-naftil-benzensulfonamida; N-bifenil-4-il-3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}-benzensulfonamida; 3-[3-(benziloksi)fenil]-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}-N-cikloheksil-benzensulfonamida; 3-[3-(3,4-dihidroizokinolin-2(1H)-ilsulfonil)fenil]-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1il]propannitrila; 3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}-N,N-dietil-benzensulfonamida; 3-{3-[(4-etilpiperazin-1-il)sulfonil]fenil}-3-[4-(7H-pirolo[2,3-d]-pirimidin-4-il)-1H-pirazol-1-il]propannitrila; N-1,3-benzodioksol-5-il-3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-etil}benzensulfonamida; 3-{3-[(2,6-dimetilmorfolin-4-il)sulfonil]fenil}-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 3-{3-[(4-oksopiperidin-1-il)sulfonil]fenil}-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 3-[3-(izopropilsulfonil)fenil]-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-propannitrila; 3-{3-[(cikloheksilmetil)sulfonil]fenil}-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 3-[3-(oktahidroizokinolin-2(1H)-ilsulfonil)fenil]-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 3-{3-[(2-feniletil)-sulfonil]fenil}-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; cis-4-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]cikloheksilacetonitrila; 3-cis-4-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]cikloheksilpropannitrila; cis-4-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]cikloheksankarbonitrila; 3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]cikloheksilacetonitrila; 5-({cis-4-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]cikloheksil}tio)-1H-1,2,4-triazol-3-amina; [cis-4-[4-(7H-Pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-1-(1H-1,2,4-triazol-1-il)ciklo-heksil] acetonitrila; 3-[3-(piperazin-1-ilsulfonil)fenil]-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-3-[3-(tiomorfolin-4-ilsulfonil)-fenil]propannitrila; 3-{3-[(4-hidroksipiperidin-1-il)sulfonil]fenil}-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol -1-il]propannitrila; 3-[3-(izobutilsulfonil)fenil]-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-propannitrila; 3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-3-{3-[(tetrahidro-2H-piran-4-ilmetil)sulfonil]fenil}propannitrila; 3-{3-[(3-furilmetil)sulfonil]fenil}-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 3-{3-[(1,1-dioksidotiomorfolin-4-il)sulfonil]fenil}-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1il]propannitrila; 3-{3-[(piridin-4-ilmetil)sulfonil]fenil}-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 3-{3-hidroksi-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propil}-N,N-dimetil-benzensulfonamida; 3-{1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]but-3-en-1-il}benzonitrila; 4-{1-[1-(3-bromofenil)but-3-en-1-il]-1H-pirazol-4-il}-7H-pirolo[2,3-d]pirimidina; 3-{4,4-difluoro-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]but-3-en-1-il}-benzonitrila; 4-(1-{4,4-difluoro-1-[3-(morfolin-4-ilsulfonil)fenil]but-3-en-1-il}-1H-pirazol-4-il)-7H-pirolo[2,3-d]pirimidina; 4-(1-{1-[3-(etilsulfonil)fenil]-4,4-difluorobut-3-en-1-il}-1H-pirazol-4-il)-7H-pirolo[2,3-d]pirimidina; 4-(1-{1-[3-(benziloksi)fenil]-4,4-difluorobut-3-en-1-il}-1H-pirazol-4-il)-7H-pirolo[2,3-d]-pirimidina; 4-(1-{4,4-difluoro-1-[3-(metilsulfonil)fenil]but-3-en-1-il}-1H-pirazol-4-il)-7H-pirolo[2,3-d]pirimidina; 3-{[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]metil} benzonitrila; 3-{1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]-butil}benzonitrila; 4-(1-{1-[3-(etilsulfonil)fenil]-4,4-difluorobutil}-1H-pirazol-4-il)-7H-pirolo[2,3-d]-pirimidina; 4-[1-(1-ciklopentilbut-3-en-1-il)-1H-pirazol-4-il]-7H-pirolo[2,3-d]pirimidina; 4-[1-(1-ciklopentilbutil)-1H-pirazol-4-il]-7H-pirolo[2,3-d]pirimidina; 4-[1-(1-ciklopentil-4,4-difluorobut-3-en-1-il)-1H-pirazol-4-il]-7H-pirolo[2,3-d]pirimidina; 4-{1-[4,4-difluoro-1-(tetrahidrofuran-3-il)but-3-en-1-il]-1H-pirazol-4-il}-7H-pirolo[2,3-d]pirimidina; 4-[1-(1-ciklopropil-4,4-difluorobut-3-en-1-il)-1H-pirazol-4-il]-7H-pirolo[2,3-d]pirimidina; 4-[1-(1-ciklopentil-4,4-difluorobutil)-1H-pirazol-4-il]-7H-pirolo[2,3-d]pirimidina; 3-(1-metilciklopentil)-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 1-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}ciklopropan-karbonitrila; 3-[1-(metilsulfonil)pirolidin-3-il]-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 4-{1-[2,2,2-trifluoro-1-(1H-imidazol-2-ilmetil)etil]-1H-pirazol-4-il} -7H-pirolo[2,3-d]pirimidina; 4-(1-(1R)-2,2,2-trifluoro-1-[(4-metil-1,3-tiazol-2-il)metil]etil-1H-pirazol-4-il)-7H-pirolo[2,3-d]pirimidina; 4-{1-[1-(5-bromopiridin-3-il)-4,4-difluorobut-3-en-1-il]-1H-pirazol-4-il}-7H-pirolo[2,3-d]pirimidina; 5-{4,4-difluoro-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]but-3-en-1-il}nikotinonitrila; 3-[3-(pirolidin-1-ilsulfonil)-fenil]-3-[4-(7H-pirolo¬[2,3-d]-pirimidin-4-il)-1H-pirazol-1-il]-propannitrila; N-benzil-3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}-N-metilbenzensulfonamida; 3-{[(3-{2-cijano-1-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}-fenil)sulfonil]metil}-benzonitrila; 3-{3-[(2-naftilmetil)-sulfonil]-fenil}-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; 3-{3-[(1-feniletil)sulfonil]-fenil}-3-[4-(7H-pirolo[2,3-d]-pirimidin-4-il)-1H-pirazol-1-il]-propannitrila; 3-{2-cijano-1-[4-(7H-pirolo-[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}-N-(2-morfolin-4-iletil)-benzensulfonamida; 3-{2-cijano-1-[4-(7H-pirolo-[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}-N-[(1S)-1-feniletil]benzensulfonamida; 3-{2-cijano-1-[4-(7H-pirolo-[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}-N-fenil-benzamida; 3-{2-cijano-1-[4-(7H-pirolo-[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]etil}-N-(tetrahidrofuran-2-il-metil)benzensulfonamida; 3-{3-[(cikopropilmetil)sulfonil]fenil}-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitril trifluoroacetata; 3-{3-[(4-metilpiperazin-1-il)-sulfonil]fenil}-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; i 3-{3-[(1-oksidotiomorfolin-4-il)sulfonil]fenil}-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitrila; ili njihove farmacutski prihvatljive soli.
9. Farmaceutski sastav koji sadrži spoj koji je 3-ciklopentil-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitril; ili njegovu farmaceutski prihvatljivu sol; i farmaceutski prihvatljiv nosač; pri čemu je navedeni sastav pogodan za oralnu primjenu i za osiguravanje produženog oslobađanja navedenog spoja ili navedene soli.
10. Farmaceutski sastav koji sadrži spoj koji je (R)-3-ciklopentil-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitril; ili njegovu farmaceutski prihvatljivu sol; i farmaceutski prihvatljiv nosač; pri čemu je navedeni sastav pogodan za oralnu primjenu i za osiguravanje produženog oslobađanja navedenog spoja ili navedene soli.
11. Farmaceutski sastav koji sadrži spoj koji je 3-ciklopropil-3-[4-(7H-pirolo[2,3-d]pirimidin-4il)-pirazol-1-il]-propionitril; ili njegovu farmaceutski prihvatljivu sol; i farmaceutski prihvatljiv nosač; pri čemu je navedeni sastav pogodan za oralnu primjenu i za osiguravanje produženog oslobađanja navedenog spoja ili navedene soli.
12. Farmaceutski sastav prema bilo kojem od patentnih zahtjeva 1 do 11, pri čemu je navedeni sastav oblika jedinice doziranja.
13. Farmaceutski sastav prema zahtjevu 12, pri čemu je navedeni oblik jedinice doziranja tableta.
14. Farmaceutski sastav prema zahtjevu 12, pri čemu je navedeni oblik jedinice doziranja kapsula.
15. Farmaceutski sastav prema zahtjevu 12, pri čemu navedeni oblik jedinice doziranja dalje sadrži enteričnu oblogu.
16. Farmaceutski sastav prema zahtjevu 12, pri čemu navedeni oblik jedinice doziranja sadrži od oko 5 do oko 1000 mg navedenog spoja ili navedene soli.
17. Farmaceutski sastav prema bilo kojem od patentnih zahtjeva 1 do 11, pri čemu navedeni nosač sadrži jedan ili više ekscipijenata izabranih od laktoze, dekstroze, saharoze, sorbitola, manitola, škrobova, gume akacije, kalcijevog fosfata, alginata, tragakanta, želatine, kalcijevog silikata, mikrokristalične celuloze, polivinilpirolidona, celuloze, vode, sirupa i metil celuloze.
18. Farmaceutski sastav prema bilo kojem od patentnih zahtjeva 1 do 11, pri čemu navedeni nosač sadrži mikrokristaličnu celulozu.
19. Farmaceutski sastav prema bilo kojem od patentnih zahtjeva 1 do 11, pri čemu navedeni nosač sadrži laktozu.
20. Farmaceutski sastav prema bilo kojem od patentnih zahtjeva 1 do 11, za uporabu u postupku liječenja bolesti izabranih od kaheksije, mijeloproliferativnog poremećaja i raka kod pacijenta.
21. Farmaceutski sastav za upotrebu prema zahtjevu 20, pri čemu je bolest mijeloproliferativni poremećaj.
22. Farmaceutski sastav za upotrebu prema zahtjevu 21, pri čemu je mijeloproliferativni poremećaj policitemija vera (PV), esencijalna trombocitemija (ET), mijeloidna metaplazija s mijelofibrozom (MMM), kronična mijeloična leukemija (CML), kronična mijelomonocitna leukemija (CMML), hipereozinofilni sindrom (HES) ili sistemska mastocitna bolest (SMCD).
23. Farmaceutski sastav za upotrebu prema zahtjevu 21, pri čemu je mijeloproliferativni poremećaj policitemija vera (PV).
24. Farmaceutski sastav za upotrebu prema zahtjevu 21, pri čemu je mijeloproliferativni poremećaj esencijalna trombocitemija (ET).
25. Farmaceutski sastav za upotrebu prema zahtjevu 21, pri čemu je mijeloproliferativni poremećaj mijeloidna metaplazija s mijelofibrozom (MMM).
26. Farmaceutski sastav za upotrebu prema zahtjevu 21, pri čemu je mijeloproliferativni poremećaj kronična mijeloična leukemija (CML).
27. Farmaceutski sastav za upotrebu prema zahtjevu 21, pri čemu je mijeloproliferativni poremećaj kronična mijelomonocitna leukemija (CMML).
28. Farmaceutski sastav za upotrebu prema zahtjevu 21, pri čemu je navedena bolest rak.
29. Farmaceutski sastav za upotrebu prema zahtjevu 28, pri čemu je navedeni rak multipli mijelom.
30. Farmaceutski sastav za upotrebu prema zahtjevu 28, pri čemu je navedeni rak rak gušterače.
31. Farmaceutski sastav za upotrebu prema zahtjevu 28, pri čemu je navedeni rak leukemija.
32. Farmaceutski sastav za upotrebu prema zahtjevu 28, pri čemu je navedeni rak limfom.
33. Farmaceutski sastav za upotrebu prema zahtjevu 28, pri čemu je navedeni rak akutna mijeloična leukemija.
34. Farmaceutski sastav za upotrebu prema zahtjevu 28, pri čemu je navedena bolest rak dojke.
35. Farmaceutski sastav za upotrebu prema zahtjevu 28, pri čemu je navedeni rak rak pluća.
36. Farmaceutski sastav za upotrebu prema zahtjevu 28, pri čemu je navedeni rak rak glave i vrata.
37. Farmaceutski sastav za upotrebu prema zahtjevu 28, pri čemu je navedeni rak izabran od raka prostate, raka bubrega, raka jetre, raka želuca, raka štitne žlijezde, glioblastoma, Kaposijevog sarkoma, Castlemanove bolesti, melanoma, T-staničnog kožnog limfoma (CTCL), B-staničnog kožnog limfoma, Sezary sindroma, "mycosis fungoides" (kronični T-stanični limfom), akutne limfoblastične leukemije i kolorektalnog raka.
38. Farmaceutski sastav za upotrebu prema zahtjevu 20, pri čemu navedena kaheksija proizlazi iz ili je povezana s rakom.
HRP20150837TT 2005-12-13 2015-08-06 Heteroaril supstituirani pirolo[2,3-b]piridini i pirolo[2,3-b]pirimidini kao inhibitori janus kinaze HRP20150837T2 (hr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US74990505P 2005-12-13 2005-12-13
US81023106P 2006-06-02 2006-06-02
US85062506P 2006-10-10 2006-10-10
US85687206P 2006-11-03 2006-11-03
US85940406P 2006-11-16 2006-11-16
EP11152708.1A EP2348023B9 (en) 2005-12-13 2006-12-12 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors

Publications (2)

Publication Number Publication Date
HRP20150837T1 true HRP20150837T1 (hr) 2015-09-11
HRP20150837T2 HRP20150837T2 (hr) 2017-04-07

Family

ID=37903501

Family Applications (7)

Application Number Title Priority Date Filing Date
HR20110903T HRP20110903T1 (hr) 2005-12-13 2011-12-01 Heteroaril supstituirani pirolo[2,3-b]piridini i pirolo[2,3-b]pirimidini kao inhibitori janus kinaze
HRP20150837TT HRP20150837T2 (hr) 2005-12-13 2015-08-06 Heteroaril supstituirani pirolo[2,3-b]piridini i pirolo[2,3-b]pirimidini kao inhibitori janus kinaze
HRP20160112TT HRP20160112T1 (hr) 2005-12-13 2016-02-02 HETEROARIL SUPSTITUIRANI PIROLO[2,3-b]PIRIDINI I PIROLO[2,3-b]PIRIMIDINI KAO INHIBITORI JANUS KINAZE
HRP20170090TT HRP20170090T1 (hr) 2005-12-13 2017-01-19 Heteroaril supstituirani pirolo[2,3-b]piridini i pirolo[2,3-b]pirimidini kao inhibitori janus kinaze
HRP20170162TT HRP20170162T1 (hr) 2005-12-13 2017-02-01 HETEROARIL SUPSTITUIRANI PIROLO[2,3-b]PIRIDINI I PIROLO[2,3-b]PIRIMIDINI KAO INHIBITORI JANUS KINAZE
HRP20170200TT HRP20170200T1 (hr) 2005-12-13 2017-02-07 HETEROARIL SUPSTITUIRANI PIROLO[2,3-b]PIRIDINI I PIROLO[2,3-b]PIRIMIDINI KAO INHIBITORI JANUS KINAZE
HRP20181912TT HRP20181912T1 (hr) 2005-12-13 2018-11-16 Derivati pirolo[2,3-d]pirimidina kao inhibitori janus kinaze

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HR20110903T HRP20110903T1 (hr) 2005-12-13 2011-12-01 Heteroaril supstituirani pirolo[2,3-b]piridini i pirolo[2,3-b]pirimidini kao inhibitori janus kinaze

Family Applications After (5)

Application Number Title Priority Date Filing Date
HRP20160112TT HRP20160112T1 (hr) 2005-12-13 2016-02-02 HETEROARIL SUPSTITUIRANI PIROLO[2,3-b]PIRIDINI I PIROLO[2,3-b]PIRIMIDINI KAO INHIBITORI JANUS KINAZE
HRP20170090TT HRP20170090T1 (hr) 2005-12-13 2017-01-19 Heteroaril supstituirani pirolo[2,3-b]piridini i pirolo[2,3-b]pirimidini kao inhibitori janus kinaze
HRP20170162TT HRP20170162T1 (hr) 2005-12-13 2017-02-01 HETEROARIL SUPSTITUIRANI PIROLO[2,3-b]PIRIDINI I PIROLO[2,3-b]PIRIMIDINI KAO INHIBITORI JANUS KINAZE
HRP20170200TT HRP20170200T1 (hr) 2005-12-13 2017-02-07 HETEROARIL SUPSTITUIRANI PIROLO[2,3-b]PIRIDINI I PIROLO[2,3-b]PIRIMIDINI KAO INHIBITORI JANUS KINAZE
HRP20181912TT HRP20181912T1 (hr) 2005-12-13 2018-11-16 Derivati pirolo[2,3-d]pirimidina kao inhibitori janus kinaze

Country Status (36)

Country Link
US (16) US7598257B2 (hr)
EP (10) EP2474545B1 (hr)
JP (4) JP5017278B2 (hr)
KR (4) KR101391900B1 (hr)
CN (4) CN103214483B (hr)
AR (1) AR057995A1 (hr)
AT (1) ATE525374T1 (hr)
AU (1) AU2006326548B2 (hr)
BR (1) BRPI0619817B8 (hr)
CA (1) CA2632466C (hr)
CR (2) CR10065A (hr)
CY (8) CY1112762T1 (hr)
DK (7) DK2343299T3 (hr)
EA (3) EA036785B1 (hr)
EC (2) ECSP088540A (hr)
ES (10) ES2612196T3 (hr)
FR (1) FR17C1013I2 (hr)
HK (5) HK1124840A1 (hr)
HR (7) HRP20110903T1 (hr)
HU (7) HUE032337T2 (hr)
IL (3) IL192019A (hr)
LT (5) LT3184526T (hr)
LU (1) LU92137I2 (hr)
ME (1) ME01312B (hr)
MX (1) MX346183B (hr)
MY (2) MY162590A (hr)
NZ (2) NZ778831A (hr)
PL (7) PL2474545T3 (hr)
PT (7) PT3184526T (hr)
RS (7) RS55632B1 (hr)
SG (3) SG10202003901UA (hr)
SI (7) SI2343299T1 (hr)
TW (6) TWI630207B (hr)
UA (2) UA98449C2 (hr)
WO (1) WO2007070514A1 (hr)
ZA (1) ZA200805165B (hr)

Families Citing this family (380)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005105814A1 (en) * 2004-04-28 2005-11-10 Incyte Corporation Tetracyclic inhibitors of janus kinases
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
WO2007031739A1 (en) * 2005-09-16 2007-03-22 Astrazeneca Ab Heterobicyclic compounds as glucokinase activators
EP2270014A1 (en) 2005-09-22 2011-01-05 Incyte Corporation Azepine inhibitors of janus kinases
CN103626742B (zh) * 2005-11-01 2017-04-26 塔格根公司 激酶的联-芳基间-嘧啶抑制剂
US8133900B2 (en) * 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en) * 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
ES2612196T3 (es) * 2005-12-13 2017-05-12 Incyte Holdings Corporation Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas sustituidas con heteroarilo como inhibidores de quinasas Janus
SI1962830T1 (sl) * 2005-12-23 2013-07-31 Glaxosmithkline Llc Azaindolni inhibitorji kinaz Aurora
AU2007236707C1 (en) * 2006-04-03 2012-05-24 Astellas Pharma Inc. Hetero compound
EP2001884A1 (en) 2006-04-05 2008-12-17 Vertex Pharmaceuticals, Inc. Deazapurines useful as inhibitors of janus kinases
ES2402789T3 (es) 2006-11-20 2013-05-08 President And Fellows Of Harvard College Métodos, composicones y kits para tratar dolor y prurito
EP2121692B1 (en) * 2006-12-22 2013-04-10 Incyte Corporation Substituted heterocycles as janus kinase inhibitors
CL2008001709A1 (es) * 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
MX342814B (es) * 2007-06-13 2016-10-13 Incyte Holdings Corp Sales de inhibidor de janus cinasa (r)-3-(4-7h-pirrolo[2,3-d]pirim idin-4-il)-1h-pirazol-1-il)-3-ciclopentilpropanitrilo.
CA2692379A1 (en) * 2007-07-02 2009-01-08 Boehringer Ingelheim International Gmbh Antiproliferative compounds based on 5-membered heterocycles
WO2009032338A1 (en) * 2007-09-09 2009-03-12 University Of Florida Research Foundation Apratoxin therapeutic agents: mechanism and methods of treatment
WO2009049028A1 (en) * 2007-10-09 2009-04-16 Targegen Inc. Pyrrolopyrimidine compounds and their use as janus kinase modulators
EP2211620B1 (en) * 2007-10-25 2013-12-25 Merck Sharp & Dohme Corp. 3-PYRAZIN SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AS JANUS KINASE INHIBITORS FOR THE TREATMENT OF CANCER DISEASES
CN101910152B (zh) * 2007-11-16 2014-08-06 因塞特公司 作为janus激酶抑制剂的4-吡唑基-n-芳基嘧啶-2-胺和4-吡唑基-n-杂芳基嘧啶-2-胺
BRPI0908433A2 (pt) * 2008-02-06 2019-09-24 Novartis Ag pirrolo[2,3-d]piridinas e empregos destas como inibidores tirosina cinase
US20110105436A1 (en) * 2008-03-10 2011-05-05 Auckland Uniservices Limited Heteroaryl compounds, compositions, and methods of use in cancer treatment
MX2010010012A (es) * 2008-03-11 2010-10-20 Incyte Corp Derivados de azetidina y ciclobutano como inhibidores de jak.
US8278335B2 (en) * 2008-04-21 2012-10-02 Merck Sharp & Dohme Corp. Inhibitors of Janus kinases
CA2722326A1 (en) * 2008-04-24 2009-10-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
AR071717A1 (es) 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
CA2727928A1 (en) * 2008-06-18 2009-12-23 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
PE20110063A1 (es) * 2008-06-20 2011-02-16 Genentech Inc DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK
KR20110033223A (ko) * 2008-06-20 2011-03-30 제넨테크, 인크. 트리아졸로피리딘 ｊａｋ 억제제 화합물 및 방법
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
JOP20190230A1 (ar) * 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
US8765727B2 (en) * 2009-01-23 2014-07-01 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
CA2762174C (en) * 2009-05-22 2018-02-20 Incyte Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
KR20120030447A (ko) 2009-05-22 2012-03-28 인사이트 코포레이션 Ｊａｋ 저해물질로서 ３-［４-（７ｈ-피롤로［２,３-ｄ］피리미딘-４-일）-１ｈ-피라졸-１-일］옥탄- 또는 헵탄-니트릴
CN102459267B (zh) 2009-06-08 2014-11-26 武田药品工业株式会社 用作jak抑制剂的二氢吡咯并萘啶酮化合物
PE20120493A1 (es) 2009-06-29 2012-05-20 Incyte Corp Pirimidinonas como inhibidores de pi3k
JP6205133B2 (ja) 2009-07-10 2017-09-27 プレジデント アンド フェローズ オブ ハーバード カレッジ 抗炎症剤としての恒久的に荷電したナトリウムおよびカルシウムチャンネルブロッカー
TWI466885B (zh) 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US9029359B2 (en) 2009-09-04 2015-05-12 Biogen Idec Ma, Inc. Heteroaryl Btk inhibitors
TW201120041A (en) 2009-09-10 2011-06-16 Hoffmann La Roche Inhibitors of JAK
KR20190082985A (ko) * 2009-10-02 2019-07-10 아벡신 에이에스 소염제 2-옥소티아졸 및 2-옥소옥사졸
EA021478B1 (ru) * 2009-10-09 2015-06-30 Инсайт Корпорейшн ГИДРОКСИЛЬНЫЕ, КЕТО И ГЛЮКУРОНИДНЫЕ ПРОИЗВОДНЫЕ 3-(4-(7Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1Н-ПИРАЗОЛ-1-ИЛ)-3-ЦИКЛОПЕНТИЛПРОПАННИТРИЛА
US8389728B2 (en) * 2009-11-06 2013-03-05 The Arizona Board Of Regents Pollen tube stimulants from Arabidopsis pistils
WO2011103423A1 (en) 2010-02-18 2011-08-25 Incyte Corporation Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
WO2011109217A2 (en) * 2010-03-02 2011-09-09 Immunodiagnostics, Inc. Methods of treating or preventing rna polymerase dependent viral disorders by administration of jak2 kinase inhibitors
RS60680B1 (sr) * 2010-03-10 2020-09-30 Incyte Holdings Corp Piperidin-4-il azetidin derivati kao inhibitori jak1
AU2015205858B2 (en) * 2010-03-10 2017-04-13 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
WO2011130146A1 (en) 2010-04-14 2011-10-20 Array Biopharma Inc. 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
SG10201503983QA (en) * 2010-05-21 2015-06-29 Incyte Corp Topical Formulation for a JAK Inhibitor
CN103119045B (zh) 2010-08-20 2016-02-17 和记黄埔医药（上海）有限公司 吡咯并嘧啶化合物及其用途
AU2011305315A1 (en) * 2010-09-24 2013-03-28 The Regents Of The University Of Michigan Deubiquitinase inhibitors and methods for use of the same
CA2816088A1 (en) 2010-10-28 2012-05-03 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
EP2640725B1 (en) 2010-11-19 2015-01-07 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
EA036970B1 (ru) * 2010-11-19 2021-01-21 Инсайт Холдингс Корпорейшн Применение {1-{1-[3-фтор-2-(трифтометил)изоникотиноил] пиперидин-4-ил}-3-[4-(7h-пирроло[2,3-d]пиримидин-4-ил)-1н-пиразол-1-ил]азетидин-3-ил}ацетонитрила для лечения заболеваний, связанных с активностью jak1
TW201249845A (en) * 2010-11-19 2012-12-16 Incyte Corp Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
US9073895B2 (en) * 2010-12-16 2015-07-07 Boehringer Ingelheim International Gmbh Biarylamide inhibitors of leukotriene production
AR084366A1 (es) 2010-12-20 2013-05-08 Incyte Corp N-(1-(fenil sustituido)etil)-9h-purin-6-aminas como inhibidores de pi3k
MX357939B (es) 2011-02-18 2018-07-31 Novartis Pharma Ag Terapia de combinacion de inhibidor de objetivo de rapamicina en mamifero/janus cinasa (mtor/jak).
CN103476752B (zh) * 2011-02-24 2016-09-28 赛福伦公司 取代的芳香族硫化合物及其使用方法
BR112013024267A2 (pt) 2011-03-22 2018-06-26 Advinus Therapeutics Ltd compostos tricíclicos fundidos substituídos, composições e aplicações medicinais dos mesmos.
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
JP2014513728A (ja) * 2011-05-17 2014-06-05 プリンシピア バイオファーマ インコーポレイテッド チロシンキナーゼ阻害剤としてのアザインドール誘導体
BR112013032125A2 (pt) 2011-06-14 2016-12-13 Novartis Ag combinação de panobinostat e ruxolitinibe no tratamento de câncer do tipo neoplasia mieloproliferativa
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
BR112014000314A2 (pt) 2011-07-08 2017-01-10 Novartis Ag derivados de pirrolo pirimidina
WO2013023119A1 (en) 2011-08-10 2013-02-14 Novartis Pharma Ag JAK P13K/mTOR COMBINATION THERAPY
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
KR101982475B1 (ko) 2011-09-02 2019-05-27 인사이트 홀딩스 코포레이션 Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
WO2013040863A1 (en) * 2011-09-22 2013-03-28 Merck Sharp & Dohme Corp. Cycloalkylnitrile pyrazole carboxamides as janus kinase inhibitors
AU2012323399A1 (en) * 2011-10-12 2014-05-29 Array Biopharma Inc. 5,7-substituted-imidazo[1,2-c]pyrimidines
BR112014013224B1 (pt) * 2011-11-30 2023-03-07 Emory University Inibidores de jak antivirais úteis no tratamento ou prevenção de infecções retrovirais e outras infecções virais
US10821111B2 (en) 2011-11-30 2020-11-03 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
US8993756B2 (en) * 2011-12-06 2015-03-31 Merck Sharp & Dohme Corp. Pyrrolopyrimidines as janus kinase inhibitors
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
WO2013173506A2 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
AR091079A1 (es) 2012-05-18 2014-12-30 Incyte Corp Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak
IN2014DN10670A (hr) 2012-06-15 2015-08-28 Concert Pharmaceuticals Inc
US20150197525A1 (en) 2012-06-15 2015-07-16 Concert Pharmaceuticals, Inc. Deuterated derivatives of ruxolitinib
KR102427777B1 (ko) 2012-06-26 2022-08-01 델 마 파마슈티컬스 디안하이드로갈락티톨, 디아세틸디안하이드로갈락티톨, 디브로모둘시톨, 또는 그의 유사체 또는 유도체를 이용하여 유전학적 다형성이 있는 환자에 있어서 티로신-키나아제-억제제 내성 악성종양, ahi1 조절곤란 또는 돌연변이를 치료하는 방법
CA2879603A1 (en) 2012-07-27 2014-01-30 Ratiopharm Gmbh Oral dosage forms for modified release comprising ruxolitinib
RU2666538C2 (ru) * 2012-08-02 2018-09-11 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Замещенные пирролы, активные в качестве ингибиторов киназ
IN2015DN02008A (hr) 2012-09-21 2015-08-14 Advinus Therapeutics Ltd
RU2619465C2 (ru) * 2012-10-26 2017-05-16 Ф. Хоффманн-Ля Рош Аг Ингибиторы тирозинкиназы брутона
US9181271B2 (en) 2012-11-01 2015-11-10 Incyte Holdings Corporation Tricyclic fused thiophene derivatives as JAK inhibitors
RS62329B1 (sr) * 2012-11-15 2021-10-29 Incyte Holdings Corp Dozni oblici ruksolitiniba sa produženim vremenom oslobađanja
US9310374B2 (en) 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
US10130632B2 (en) 2012-11-27 2018-11-20 Beth Israel Deaconess Medical Center, Inc. Methods for treating renal disease
EP2928459A4 (en) * 2012-12-06 2016-10-26 Baruch S Blumberg Inst FUNCTIONALIZED BENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION
US9260426B2 (en) * 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
CA2899137C (en) 2013-01-29 2021-07-13 Avexxin As Antiinflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds
KR101828662B1 (ko) * 2013-02-12 2018-02-12 코니카 미놀타 가부시키가이샤 유기 일렉트로루미네센스 소자 및 조명 장치
ES2900492T3 (es) 2013-03-06 2022-03-17 Incyte Holdings Corp Procesos y productos intermedios para elaborar un inhibidor de JAK
US20140343034A1 (en) 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
PT3231801T (pt) 2013-05-17 2019-05-24 Incyte Corp Sal de bipirazole como inibidor da jak
EA201690357A1 (ru) 2013-08-07 2016-07-29 Инсайт Корпорейшн Лекарственные формы с замедленным высвобождением для ингибитора jak1
AU2014309017A1 (en) 2013-08-20 2016-03-10 Incyte Corporation Survival benefit in patients with solid tumors with elevated C-reactive protein levels
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
WO2015054283A1 (en) * 2013-10-08 2015-04-16 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9440977B2 (en) * 2013-10-15 2016-09-13 Bohan Jin Compositions, uses and methods for their preparation
JP2016538305A (ja) 2013-11-27 2016-12-08 ノバルティス アーゲー Ｊａｋ、ｃｄｋおよびｐｉｍの阻害剤を含む組合せ療法
PT3077395T (pt) 2013-12-05 2018-01-03 Pfizer Pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo e pirrolo[2,3-d]piridinilo acrilamidas
JP6367545B2 (ja) * 2013-12-17 2018-08-01 コンサート ファーマシューティカルズ インコーポレイテッド ルキソリチニブの重水素化誘導体
CN110229159B (zh) * 2013-12-18 2021-08-24 康塞特医药品有限公司 卢索替尼的氘代衍生物
KR102261733B1 (ko) * 2013-12-18 2021-06-04 콘서트 파마슈티컬즈, 인크. 룩소리티닙의 중수소화된 유도체
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
WO2015131080A1 (en) 2014-02-28 2015-09-03 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
PT3110409T (pt) 2014-02-28 2018-11-07 Incyte Corp Inibidores de jak1 para o tratamento de síndromes mielodisplásicas
US20150259420A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
CA2945151C (en) 2014-04-08 2022-08-02 Incyte Corporation Treatment of b-cell malignancies by a combination jak and pi3k inhibitors
EP3137471A1 (en) 2014-04-30 2017-03-08 Incyte Corporation Processes of preparing a jak1 inhibitor and new forms thereto
RU2564891C1 (ru) * 2014-05-27 2015-10-10 Александр Александрович Кролевец Способ получения нанокапсул цитокининов
EP4233870A3 (en) * 2014-05-28 2024-01-24 Onco Tracker, Inc. Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
CN105218548A (zh) * 2014-06-09 2016-01-06 上海海和药物研究开发有限公司 一种新型杂环化合物及其制备方法和作为激酶抑制剂的用途
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
CA2955009A1 (en) * 2014-07-14 2016-01-21 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
NZ629796A (en) * 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
GB201413695D0 (en) 2014-08-01 2014-09-17 Avexxin As Compound
HRP20220738T1 (hr) 2014-08-11 2022-08-19 Acerta Pharma B.V. Terapijske kombinacije inhibitora btk, inhibitora pd-1 i/ili inhibitora pd-l1
WO2016024232A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor
EP3179991B1 (en) 2014-08-11 2021-10-06 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a bcl-2 inhibitor
US11311512B2 (en) 2014-08-12 2022-04-26 Monash University Lymph directing prodrugs
EP3183252B1 (en) * 2014-08-21 2021-05-12 ratiopharm GmbH Oxalate salt of ruxolitinib
RU2718914C2 (ru) 2014-09-13 2020-04-15 Новартис Аг Сочетанные способы лечения с использованием ингибиторов alk
CN105524067A (zh) * 2014-09-28 2016-04-27 江苏柯菲平医药股份有限公司 4-取代吡咯并[2,3-d]嘧啶化合物及其用途
ES2774448T3 (es) 2014-10-03 2020-07-21 Novartis Ag Terapias de combinación
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CR20170143A (es) 2014-10-14 2017-06-19 Dana Farber Cancer Inst Inc Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
WO2016063294A2 (en) * 2014-10-20 2016-04-28 Msn Laboratories Private Limited Process for the preparation of (r)-3-(4-(7h-pyrrolo[2,3-d], pyrimidin-4-yl)-1 h-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate and its polymorphs thereof
GB2535427A (en) 2014-11-07 2016-08-24 Nicoventures Holdings Ltd Solution
CZ2014773A3 (cs) 2014-11-10 2016-05-18 Zentiva, K.S. Soli (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu
CN105777754B (zh) * 2014-12-16 2019-07-26 北京赛林泰医药技术有限公司 吡咯并嘧啶化合物
US20160251376A1 (en) 2015-02-27 2016-09-01 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
MY187502A (en) 2015-02-27 2021-09-24 Incyte Corp Salts of pi3k inhibitor and processes for their preparation
SG11201706756VA (en) 2015-03-10 2017-09-28 Aduro Biotech Inc Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
KR101859170B1 (ko) * 2015-04-17 2018-05-17 광주과학기술원 트리아졸 화합물 및 이의 용도
CA2982493C (en) * 2015-04-29 2020-01-07 Hao Wu Jak inhibitors
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US9840503B2 (en) 2015-05-11 2017-12-12 Incyte Corporation Heterocyclic compounds and uses thereof
WO2017004134A1 (en) 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
CZ2015496A3 (cs) 2015-07-14 2017-01-25 Zentiva, K.S. Krystalické formy solí (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu a jejich příprava
WO2017011720A1 (en) * 2015-07-16 2017-01-19 Signal Pharmaceuticals, Llc Solod forms 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d] oxazol-6-yl)17h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
EP4378957A2 (en) 2015-07-29 2024-06-05 Novartis AG Combination therapies comprising antibody molecules to pd-1
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
RU2018107695A (ru) 2015-08-03 2019-09-05 Президент Энд Феллоуз Оф Гарвард Колледж Заряженные блокаторы ионных каналов и способы их применения
US9708333B2 (en) 2015-08-12 2017-07-18 Incyte Corporation Fused bicyclic 1,2,4-triazine compounds as TAM inhibitors
US10053465B2 (en) 2015-08-26 2018-08-21 Incyte Corporation Pyrrolopyrimidine derivatives as TAM inhibitors
EP3344624B8 (en) 2015-09-02 2023-11-29 Takeda Pharmaceutical Company Limited Tyk2 inhibitors and uses thereof
CN108137482B (zh) 2015-09-08 2024-03-15 莫纳什大学 定向淋巴的前药
WO2017044720A1 (en) 2015-09-11 2017-03-16 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
SI3364958T1 (sl) 2015-10-23 2023-05-31 Navitor Pharmaceuticals, Inc. Modulatorji interakcije sestrina in gator2 ter njihova uporaba
EP3370768B9 (en) 2015-11-03 2022-03-16 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
WO2017079519A1 (en) 2015-11-06 2017-05-11 Incyte Corporation Heterocyclic compounds as pi3k-gamma inhibitors
RU2601410C1 (ru) * 2015-11-13 2016-11-10 ЗАО "Р-Фарм" {3-[(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)АЗОЛИЛ]АЗЕТИДИН-3-ИЛ}АЦЕТОНИТРИЛЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС КИНАЗ
EP3389664A4 (en) 2015-12-14 2020-01-08 Raze Therapeutics Inc. MTHFD2 CAFFEIN INHIBITORS AND USES THEREOF
CN108368115B (zh) * 2015-12-15 2020-01-03 正大天晴药业集团股份有限公司 吡咯并嘧啶化合物的盐
CN108495651A (zh) 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
JP2019502695A (ja) 2015-12-17 2019-01-31 ノバルティス アーゲー ＰＤ−１に対する抗体分子とＣ−Ｍｅｔ阻害剤との組合せおよびその使用
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
US10562904B2 (en) 2015-12-31 2020-02-18 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Synthesis process of ruxolitinib
CA3010019A1 (en) 2016-01-12 2017-07-20 James Richard BERENSON Improved methods for monitoring immune status of a subject
CZ201629A3 (cs) 2016-01-22 2017-08-02 Zentiva, K.S. Krystalické modifikace solí (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu a způsoby jejich přípravy
US10822339B2 (en) 2016-01-26 2020-11-03 Hangzhou Huadong Medicine Group Biopharmaceutical Co. Ltd Pyrrolopyrimidine five-membered azacyclic derivative and application thereof
CN105541891B (zh) * 2016-02-04 2017-11-28 东南大学 巴瑞替尼的中间体及其制备方法及由该中间体制备巴瑞替尼的方法
US11014882B2 (en) * 2016-03-09 2021-05-25 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
DK3426243T3 (da) 2016-03-09 2021-07-19 Raze Therapeutics Inc 3-phosphoglyceratdehydrogenase-inhibitorer og anvendelser deraf
GB201604318D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
LT3436461T (lt) 2016-03-28 2024-03-12 Incyte Corporation Pirolotriazino junginiai kaip tam inhibitoriai
WO2017177230A1 (en) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methods for treating cancer
EP3452039B1 (en) 2016-05-04 2024-07-03 Sun Pharmaceutical Industries, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
CN107513067A (zh) 2016-06-16 2017-12-26 北京赛林泰医药技术有限公司 含有取代环戊基的吡咯并嘧啶化合物
CN107759600A (zh) * 2016-06-16 2018-03-06 正大天晴药业集团股份有限公司 作为jak抑制剂的吡咯并嘧啶化合物的结晶
CN107513069A (zh) 2016-06-16 2017-12-26 正大天晴药业集团股份有限公司 手性吡咯并嘧啶化合物的制备方法
CN109641838A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
EP3471727B1 (en) 2016-06-21 2020-12-09 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
JP7084624B2 (ja) 2016-06-21 2022-06-15 エックス４ ファーマシューティカルズ， インコーポレイテッド Ｃｘｃｒ４阻害剤およびその使用
CN109311896B (zh) 2016-06-30 2021-08-24 株式会社大熊制药 吡唑并嘧啶衍生物作为激酶抑制剂
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
EP3492469B1 (en) 2016-07-26 2021-12-01 Suzhou Longbiotech Pharmaceuticals Co., Ltd. Compound as selective jak inhibitor, and salt and therapeutic use thereof
TW201811795A (zh) 2016-08-24 2018-04-01 美商亞闊股份有限公司 胺基－吡咯并嘧啶酮化合物及其用途
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
IT201600092051A1 (it) * 2016-09-13 2018-03-13 Alessandro Antonelli Composto medicale per il trattamento di tumori della tiroide
AU2017342464B2 (en) 2016-10-14 2021-09-16 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof
EP3528816A4 (en) 2016-10-21 2020-04-08 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
EP3538091A4 (en) 2016-11-08 2020-06-10 Navitor Pharmaceuticals, Inc. PHENYL AMINO PIPERIDINE MTORC INHIBITORS AND USES THEREOF
US20180193270A1 (en) 2016-11-29 2018-07-12 PureTech Health LLC Exosomes for delivery of therapeutic agents
WO2018106636A1 (en) 2016-12-05 2018-06-14 Raze Therapeutics, Inc. Shmt inhibitors and uses thereof
RU2644155C1 (ru) * 2016-12-12 2018-02-08 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") 2-(3-(4-(7H-пирроло[2,3-d]пиримидин-4-ил)-1H-пиразол-1-ил)-1-(этилсульфонил)азетидин-3-ил)ацетонитрила геминафтилдисульфонат в качестве ингибитора Янус киназ
WO2018115203A1 (en) 2016-12-23 2018-06-28 Bicyclerd Limited Peptide derivatives having novel linkage structures
EP3565638B8 (en) 2017-01-06 2024-04-10 BicycleRD Limited Bicycle conjugate for treating cancer
EA039344B1 (ru) * 2017-01-19 2022-01-17 Сучжоу Лонгбайотек Фармасьютикалз Ко., Лтд. Гетероциклическое соединение в качестве ингибитора jak и его соли и терапевтическое применение
TWI783978B (zh) 2017-03-08 2022-11-21 美商林伯士拉克許米公司 Tyk2抑制劑、其用途及生產方法
EP3375778A1 (en) 2017-03-14 2018-09-19 Artax Biopharma Inc. Aryl-piperidine derivatives
EP3375784A1 (en) 2017-03-14 2018-09-19 Artax Biopharma Inc. Aza-dihydro-acridone derivatives
US11339144B2 (en) 2017-04-10 2022-05-24 Navitor Pharmaceuticals, Inc. Heteroaryl Rheb inhibitors and uses thereof
JOP20180036A1 (ar) 2017-04-18 2019-01-30 Vifor Int Ag أملاح لمثبطات فروبورتين جديدة
TWI776886B (zh) 2017-04-26 2022-09-11 美商奈維特製藥公司 Sestrin-gator2交互作用之調節劑及其用途
EP3615550A1 (en) 2017-04-27 2020-03-04 BicycleTx Limited Bicyclic peptide ligands and uses thereof
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
US10745405B2 (en) 2017-05-23 2020-08-18 Theravance Biopharma R&D Ip, Llc Glucuronide prodrugs of Janus kinase inhibitors
EP3639028A4 (en) 2017-06-13 2021-04-14 Inc. Onco Tracker DIAGNOSTIC, PROGNOSTIC AND MONITORING PROCEDURES FOR MALIGNE SOLID TUMORS
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
CA3066774A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
US10899798B2 (en) 2017-06-26 2021-01-26 Bicyclerd Limited Bicyclic peptide ligands with detectable moieties and uses thereof
CN107298680A (zh) * 2017-07-12 2017-10-27 海门华祥医药科技有限公司 一种4‑氯‑7‑氮杂吲哚的生产工艺
JP7216705B2 (ja) 2017-07-28 2023-02-02 ニンバス ラクシュミ， インコーポレイテッド Ｔｙｋ２阻害剤およびその使用方法
EP3668887A1 (en) 2017-08-14 2020-06-24 Bicyclerd Limited Bicyclic peptide ligand sting conjugates and uses thereof
WO2019034868A1 (en) 2017-08-14 2019-02-21 Bicyclerd Limited CONJUGATES PEPTIDE BICYCLIC-LIGAND PPR-A AND USES THEREOF
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
CA3077739A1 (en) 2017-08-29 2019-03-07 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
US11358948B2 (en) 2017-09-22 2022-06-14 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
IL295603B2 (en) 2017-09-22 2024-03-01 Kymera Therapeutics Inc Protein compounds and their uses
AU2018342471B2 (en) 2017-09-27 2023-08-24 Incyte Corporation Salts of pyrrolotriazine derivatives useful as TAM inhibitors
CN109651424B (zh) * 2017-10-11 2021-01-22 新发药业有限公司 一种7-保护基-4-(1-氢-吡唑-4-基)吡咯[2,3-d]嘧啶的合成方法
EP3710431A4 (en) 2017-11-03 2021-07-07 Aclaris Therapeutics, Inc. SUBSTITUTED PYRROLOPYRIMIDINE JAK INHIBITORS AND METHODS FOR THEIR MANUFACTURE AND USE
US10800775B2 (en) 2017-11-03 2020-10-13 Aclaris Therapeutics, Inc. Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same
KR102034538B1 (ko) 2017-11-28 2019-10-21 주식회사한국파마 Jak 저해제 화합물, 및 이의 제조방법
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
WO2019126378A1 (en) 2017-12-19 2019-06-27 Ariya Therapeutics, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
IL275649B2 (en) 2017-12-26 2023-12-01 Kymera Therapeutics Inc IRAK joints and used in them
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
EP3737675A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. CRBN LIGANDS AND THEIR USES
CN111867581B (zh) 2018-01-29 2023-12-26 默克专利股份有限公司 Gcn2抑制剂及其用途
KR20200116481A (ko) 2018-01-29 2020-10-12 메르크 파텐트 게엠베하 Gcn2 억제제 및 이의 용도
SG11202007164UA (en) 2018-01-30 2020-08-28 Incyte Corp Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
IL311485A (en) 2018-02-16 2024-05-01 Incyte Corp JAK1 pathway inhibitors for the treatment of cytokine-related disorders
US10836769B2 (en) 2018-02-26 2020-11-17 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof
EA202091742A1 (ru) 2018-02-27 2021-02-19 Артакс Биофарма Инк. ПРОИЗВОДНЫЕ ХРОМЕНА В КАЧЕСТВЕ ИНГИБИТОРОВ ВЗАИМОДЕЙСТВИЯ TCR-Nck
WO2019171326A1 (en) 2018-03-08 2019-09-12 Novartis Ag Use of an anti-p-selectin antibody
CN110357887B (zh) * 2018-03-26 2022-09-16 武汉誉祥医药科技有限公司 取代的7H-吡咯并[2,3-d]嘧啶衍生物及其制备方法和用途
DK3773593T3 (da) 2018-03-30 2024-05-27 Incyte Corp Behandling af hidradenitis suppurativa under anvendelse af JAK-inhibitorer
JP2021519772A (ja) 2018-03-30 2021-08-12 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ 炎症性皮膚疾患のバイオマーカー
CA3097025A1 (en) 2018-04-13 2019-10-17 Incyte Corporation Biomarkers for graft-versus-host disease
JP7479293B2 (ja) 2018-04-24 2024-05-08 バーテックス ファーマシューティカルズ インコーポレイテッド プテリジノン化合物およびその使用
TWI813673B (zh) 2018-04-24 2023-09-01 德商馬克專利公司 抗增生化合物及其用途
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
CN110446713B (zh) * 2018-06-06 2022-05-24 杭州澳津生物医药技术有限公司 一种吡唑嘧啶衍生物及其用途和药物组合物
FI3813946T3 (fi) 2018-06-15 2024-06-25 Janssen Pharmaceutica Nv Rapamysiinianalogeja ja niiden käyttötapoja
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
KR20210049088A (ko) 2018-06-29 2021-05-04 인사이트 코포레이션 Axl/mer 억제제의 제형
JP6830460B2 (ja) * 2018-07-05 2021-02-17 コンサート ファーマシューティカルズ インコーポレイテッド ルキソリチニブの重水素化誘導体
EP3817748A4 (en) 2018-07-06 2022-08-24 Kymera Therapeutics, Inc. TRICYCLIC CRBN LIGANDS AND USES THEREOF
CA3224985A1 (en) 2018-07-31 2020-02-06 Loxo Oncology, Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide
US11021482B2 (en) 2018-08-10 2021-06-01 Adaris Therapeutics, Inc. Pyrrolopyrimidine ITK inhibitors
WO2020039401A1 (en) 2018-08-24 2020-02-27 Novartis Ag Treatment comprising il-1βeta binding antibodies and combinations thereof
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
JP2022500499A (ja) 2018-09-07 2022-01-04 ピク セラピューティクス， インコーポレイテッド Ｅｉｆ４ｅ阻害剤およびその使用
AU2019360941A1 (en) 2018-10-15 2021-04-29 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof
JP2022512779A (ja) 2018-10-23 2022-02-07 バイスクルテクス・リミテッド 二環式ペプチドリガンドおよびその使用
CA3117336A1 (en) 2018-10-24 2020-04-30 Navitor Pharmaceuticals, Inc. Polymorphs of (s)-2-amino-5,5-difluoro-4,4-dimethylpentanoic acid for use in modulating mtorc1
MX2021004946A (es) 2018-10-31 2021-07-15 Incyte Corp Terapia combinada para tratamiento de enfermedades hematológicas.
EP3886843A4 (en) 2018-11-30 2022-08-31 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND THEIR USES
CN113423427A (zh) 2018-11-30 2021-09-21 凯麦拉医疗公司 Irak降解剂和其用途
CN109394768B (zh) * 2018-12-10 2019-08-23 牡丹江医学院 一种治疗湿疹的药物及其制备方法
CN111320633B (zh) * 2018-12-14 2022-09-27 中国医药研究开发中心有限公司 吡咯/咪唑并六元杂芳环类化合物及其制备方法和医药用途
CN113490666A (zh) 2018-12-19 2021-10-08 奥瑞生物药品公司 作为fgfr酪氨酸激酶的抑制剂的取代的吡唑并[1,5-a]吡啶化合物
WO2020131674A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
EP3670659A1 (en) 2018-12-20 2020-06-24 Abivax Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
BR112021011894A2 (pt) 2018-12-21 2021-09-08 Daiichi Sankyo Company, Limited Composição farmacêutica
CN113348021A (zh) 2019-01-23 2021-09-03 林伯士拉克许米公司 Tyk2抑制剂和其用途
WO2020165600A1 (en) 2019-02-14 2020-08-20 Bicycletx Limited Bicyclic peptide ligand sting conjugates and uses thereof
CN111620873B (zh) * 2019-02-28 2021-12-28 沈阳药科大学 一类含哌啶的吡咯并[2,3-d]嘧啶衍生物及其制备和用途
EP3934651A1 (en) 2019-03-05 2022-01-12 Incyte Corporation Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
EP3937929A4 (en) 2019-03-11 2022-12-28 Nocion Therapeutics, Inc. CHARGED ION CHANNEL BLOCKERS AND METHODS OF USE
US10786485B1 (en) 2019-03-11 2020-09-29 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US10934263B2 (en) 2019-03-11 2021-03-02 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US10780083B1 (en) 2019-03-11 2020-09-22 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
CA3129089A1 (en) 2019-03-11 2020-09-17 Bridget Mccarthy Cole Ester substituted ion channel blockers and methods for use
WO2020191041A2 (en) 2019-03-19 2020-09-24 Incyte Corporation Biomarkers for vitiligo
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
SG11202110828UA (en) 2019-04-02 2021-10-28 Bicycletx Ltd Bicycle toxin conjugates and uses thereof
US11485750B1 (en) 2019-04-05 2022-11-01 Kymera Therapeutics, Inc. STAT degraders and uses thereof
CA3134750A1 (en) 2019-04-24 2020-10-29 Jingdan Hu A 7h-pyrrolo[2,3-d]pyrimidine jak-inhibitor
EP3962897A4 (en) 2019-05-02 2022-12-14 Aclaris Therapeutics, Inc. SUBSTITUTED PYRROLOPYRIDINES AS JAK INHIBITORS
KR102286372B1 (ko) 2019-05-27 2021-08-05 주식회사한국파마 Jak 저해제 화합물, 및 이를 포함하는 의약 조성물
CN110028509B (zh) * 2019-05-27 2020-10-09 上海勋和医药科技有限公司 作为选择性jak2抑制剂的吡咯并嘧啶类化合物、其合成方法及用途
WO2020243423A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
MA56215A (fr) * 2019-06-10 2022-04-20 Incyte Corp Traitement topique du vitiligo par un inhibiteur de jak
MX2022000016A (es) 2019-06-27 2022-02-24 Crispr Therapeutics Ag Uso de linfocitos t con receptor de antigeno quimerico e inhibidores de linfocitos citoliticos naturales para el tratamiento del cancer.
CN110305140B (zh) 2019-07-30 2020-08-04 上海勋和医药科技有限公司 二氢吡咯并嘧啶类选择性jak2抑制剂
TW202118770A (zh) 2019-07-30 2021-05-16 英商拜西可泰克斯有限公司 異質雙環肽複合物
WO2021022178A1 (en) * 2019-07-31 2021-02-04 Aclaris Therapeutics, Inc. Substituted sulfonamide pyrrolopyridines as jak inhibitors
US20220251097A1 (en) * 2019-08-01 2022-08-11 St. Jude Childrens's Research Hospital Molecules and methods related to treatment of uncontrolled cellular proliferation
AU2020345962A1 (en) 2019-09-11 2022-03-31 Vincere Biosciences, Inc. USP30 inhibitors and uses thereof
JP2022547719A (ja) 2019-09-13 2022-11-15 ニンバス サターン， インコーポレイテッド Ｈｐｋ１アンタゴニストおよびその使用
EP4041394A1 (en) 2019-09-16 2022-08-17 Novartis AG Use of high-affinity, ligand-blocking, humanized anti-t-cell immunoglobulin domain and mucin domain-3 (tim-3) igg4 antibody for the treatment of myelofibrosis
CN114450008A (zh) 2019-09-16 2022-05-06 诺华股份有限公司 Mdm2抑制剂用于治疗骨髓纤维化的用途
WO2021053559A1 (en) 2019-09-18 2021-03-25 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
CN110538183B (zh) * 2019-10-09 2021-05-04 吉林大学 一种预防和治疗小儿湿疹的组合物及其制备方法
US20210123930A1 (en) 2019-10-10 2021-04-29 Incyte Corporation Biomarkers for graft-versus-host disease
WO2021072098A1 (en) 2019-10-10 2021-04-15 Incyte Corporation Biomarkers for graft-versus-host disease
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
WO2021076124A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp)
EP4051259A4 (en) 2019-11-01 2023-11-22 Navitor Pharmaceuticals, Inc. TREATMENT METHODS USING AN MTORC1 MODULATOR
US10933055B1 (en) 2019-11-06 2021-03-02 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
BR112022008575A2 (pt) 2019-11-06 2022-08-09 Nocion Therapeutics Inc Bloqueadores de canal iônico carregado e métodos para uso
AU2020378630A1 (en) 2019-11-08 2022-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
CR20220280A (es) 2019-11-22 2022-09-02 Incyte Corp Terapia de combinación que comprende un inhibidor de alk2 y un inhibidor de jak2
US11819476B2 (en) 2019-12-05 2023-11-21 Janssen Pharmaceutica Nv Rapamycin analogs and uses thereof
IL293917A (en) 2019-12-17 2022-08-01 Kymera Therapeutics Inc Iraq joints and their uses
WO2021127283A2 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
CN115297931A (zh) 2019-12-23 2022-11-04 凯麦拉医疗公司 Smarca降解剂和其用途
EP4085056A1 (en) 2020-01-03 2022-11-09 Berg LLC Polycyclic amides as ube2k modulators for treating cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021159021A1 (en) 2020-02-05 2021-08-12 Puretech Lyt, Inc. Lipid prodrugs of neurosteroids
CN111728975A (zh) * 2020-02-25 2020-10-02 广东省检迅检测科技有限公司 用于减少运动损伤和促进运动损伤修复的组合物
CA3170411A1 (en) 2020-03-03 2021-09-10 Christopher L. Vandeusen Eif4e inhibitors and uses thereof
US11332446B2 (en) 2020-03-11 2022-05-17 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
CA3171258A1 (en) 2020-03-19 2021-09-23 Nan JI Mdm2 degraders and uses thereof
US11324750B2 (en) 2020-04-09 2022-05-10 Children's Hospital Medical Center Compositions and methods for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
WO2021206766A1 (en) 2020-04-09 2021-10-14 Children's Hospital Medical Center Sars-cov-2 infection biomarkers and uses thereof
EP3892280A3 (en) 2020-04-09 2022-01-12 Children's Hospital Medical Center Sars-cov-2 infection biomarkers and uses thereof
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
WO2021236139A1 (en) 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Novel deuterated jak inhibitor and uses thereof
CN115836065A (zh) 2020-06-02 2023-03-21 因赛特公司 制备jak1抑制剂的方法
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
KR20230031242A (ko) 2020-06-03 2023-03-07 인사이트 코포레이션 골수증식성 신생물의 치료를 위한 병용 요법
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
TW202210472A (zh) 2020-06-05 2022-03-16 美商奇奈特生物製藥公司 纖維母細胞生長因子受體激酶之抑制劑
WO2021260657A1 (en) 2020-06-26 2021-12-30 Crispr Therapeutics Ag Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
US11751108B2 (en) * 2020-08-05 2023-09-05 Qualcomm Incorporated Execution of reduced signaling handover
US20230322787A1 (en) * 2020-08-12 2023-10-12 Concert Pharmaceuticals, Inc. Process for preparing enantiomerically enriched jak inhibitors
AU2021327130A1 (en) 2020-08-17 2023-03-02 Bicycletx Limited Bicycle conjugates specific for Nectin-4 and uses thereof
CA3192055A1 (en) 2020-08-18 2022-02-24 Incyte Corporation Process and intermediates for preparing a jak1 inhibitor
WO2022040180A1 (en) 2020-08-18 2022-02-24 Incyte Corporation Process and intermediates for preparing a jak inhibitor
JP2023542137A (ja) 2020-09-16 2023-10-05 インサイト・コーポレイション 白斑の局所処置
BR112023004179A2 (pt) * 2020-09-16 2023-04-11 Axceso Biopharma Co Ltd Composto de pirimido pirimidinona e composição farmacêutica compreendendo o mesmo
CN117440814A (zh) 2020-10-02 2024-01-23 因赛特公司 用于治疗扁平苔藓的外用鲁索替尼
EP4225317A1 (en) 2020-10-08 2023-08-16 Novartis AG Use of an erk inhibitor for the treatment of myelofibrosis
EP4225316A1 (en) 2020-10-08 2023-08-16 Novartis AG Use of an erk inhibitor for the treatment of myelofibrosis
CN114437079A (zh) * 2020-10-30 2022-05-06 杭州邦顺制药有限公司 吡咯嘧啶五元氮杂环化合物的晶型
KR102551758B1 (ko) 2020-11-30 2023-07-05 주식회사한국파마 신규한 jak 특이 저해제 화합물, 및 이의 제조방법
WO2022120353A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
KR20230131189A (ko) 2020-12-02 2023-09-12 이케나 온콜로지, 인코포레이티드 Tead 억제제 및 이의 용도
JP2023552424A (ja) 2020-12-04 2023-12-15 インサイト・コーポレイション 皮膚疾患の治療のためのビタミンｄ類似体を有するｊａｋ阻害剤
AU2021396231A1 (en) 2020-12-08 2023-06-22 Incyte Corporation Jak1 pathway inhibitors for the treatment of vitiligo
CN117242080A (zh) 2020-12-18 2023-12-15 勃林格殷格翰动物保健美国公司 含硼吡唑化合物、包括其的组合物、其方法和用途
EP4274578A1 (en) 2021-01-11 2023-11-15 Incyte Corporation Combination therapy comprising jak pathway inhibitor and rock inhibitor
US20240174662A1 (en) * 2021-02-01 2024-05-30 Janssen Biotech, Inc. Small molecule inhibitors of salt inducible kinases
WO2022167457A1 (en) 2021-02-02 2022-08-11 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
JP2024506858A (ja) 2021-02-02 2024-02-15 リミナル・バイオサイエンシーズ・リミテッド Ｇｐｒ８４アンタゴニストおよびその使用
WO2022166796A1 (zh) * 2021-02-05 2022-08-11 上海齐鲁制药研究中心有限公司 嘧啶或吡啶并杂环类腺苷受体抑制剂及其制备方法和用途
IL304905A (en) 2021-02-15 2023-10-01 Kymera Therapeutics Inc IRAK4 joints and their uses
MX2023009858A (es) 2021-02-25 2023-09-12 Impact Biomedicines Inc Uso de inhibidores de proteina de bromodominio y motivo extraterminal (bet) solo o en combinacion con fedratinib o ruxolitinib como tratamiento para una malignidad hematologica tal como la mielofibrosis.
US11926625B2 (en) 2021-03-05 2024-03-12 Nimbus Saturn, Inc. HPK1 antagonists and uses thereof
EP4323066A1 (en) 2021-04-16 2024-02-21 Ikena Oncology, Inc. Mek inhibitors and uses thereof
EP4392421A1 (en) 2021-08-25 2024-07-03 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
CN118103368A (zh) 2021-08-25 2024-05-28 皮克医疗公司 Eif4e抑制剂及其用途
WO2023042224A1 (en) * 2021-09-18 2023-03-23 Natco Pharma Limited An improved process for the preparation of ruxolitinib phosphate
WO2023076161A1 (en) 2021-10-25 2023-05-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof
WO2023102559A1 (en) 2021-12-03 2023-06-08 Incyte Corporation Topical formulations of ruxolitinib with an organic amine ph adjusting agent for treatment of skin diseases
WO2023114984A1 (en) 2021-12-17 2023-06-22 Ikena Oncology, Inc. Tead inhibitors and uses thereof
CN114044777B (zh) * 2022-01-10 2022-04-19 南京佰麦生物技术有限公司 一种磷酸芦可替尼的制备方法
CN114456181A (zh) * 2022-02-21 2022-05-10 浙江乐普药业股份有限公司 一种芦可替尼的制备方法
WO2023173057A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023173053A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023211889A1 (en) 2022-04-25 2023-11-02 Ikena Oncology, Inc. Polymorphic compounds and uses thereof
US11878958B2 (en) 2022-05-25 2024-01-23 Ikena Oncology, Inc. MEK inhibitors and uses thereof
WO2024028365A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Substituted pyridone gpr84 antagonists and uses thereof
WO2024028363A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
WO2024028364A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Aryl-triazolyl and related gpr84 antagonists and uses thereof
WO2024028193A1 (en) 2022-08-03 2024-02-08 Medichem, S.A. Stable oral pharmaceutical formulation containing ruxolitinib hemifumarate
WO2024099396A1 (zh) * 2022-11-11 2024-05-16 浙江奥翔药业股份有限公司 芦可替尼晶体及其药物组合物
WO2024112894A1 (en) 2022-11-22 2024-05-30 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof

Family Cites Families (311)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2985589A (en) * 1957-05-22 1961-05-23 Universal Oil Prod Co Continuous sorption process employing fixed bed of sorbent and moving inlets and outlets
US3632836A (en) 1968-10-25 1972-01-04 Dow Chemical Co Solid curable polyepoxides modified with hydrolyzed liquid polyepoxides
US3832460A (en) 1971-03-19 1974-08-27 C Kosti Anesthetic-vasoconstrictor-antihistamine composition for the treatment of hypertrophied oral tissue
US4140755A (en) * 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
DE3036390A1 (de) 1980-09-26 1982-05-13 Troponwerke GmbH & Co KG, 5000 Köln Neue pyrrolo-pyrimidine, verfahren zu ihrer herstellung und ihre verwendung bei der herstellung von biologischen wirkstoffen
DE3220113A1 (de) * 1982-05-28 1983-12-01 Basf Ag, 6700 Ludwigshafen Difluormethoxiphenylthiophosphorsaeureester
US4402832A (en) * 1982-08-12 1983-09-06 Uop Inc. High efficiency continuous separation process
US4404335A (en) 1982-08-16 1983-09-13 The Dow Chemical Company Hydrolyzing epoxy resins in absence of solvent and in presence of oxalic acid and a phosphonium compound
US4548990A (en) * 1983-08-15 1985-10-22 Ciba-Geigy Corporation Crosslinked, porous polymers for controlled drug delivery
US4498991A (en) * 1984-06-18 1985-02-12 Uop Inc. Serial flow continuous separation process
NL8403224A (nl) 1984-10-24 1986-05-16 Oce Andeno Bv Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen.
CA1306260C (en) 1985-10-18 1992-08-11 Shionogi & Co., Ltd. Condensed imidazopyridine derivatives
US4921947A (en) 1986-03-31 1990-05-01 Eli Lilly And Company Process for preparing macrolide derivatives
JPH0710876Y2 (ja) 1989-08-31 1995-03-15 石垣機工株式会社 スクリュープレスにおける脱水筒の洗浄装置
JP2541702B2 (ja) 1989-10-11 1996-10-09 帝人株式会社 二環性ピリミジン誘導体、その製造方法およびそれを有効成分とする医薬製剤
US5403593A (en) 1991-03-04 1995-04-04 Sandoz Ltd. Melt granulated compositions for preparing sustained release dosage forms
IT1258781B (it) * 1992-01-16 1996-02-29 Zambon Spa Composizione farmaceutica oftalmica contenente n-acetilcisteina e polivinilalcol
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
FR2695126B1 (fr) 1992-08-27 1994-11-10 Sanofi Elf Dérivés d'acide thiényl ou pyrrolyl carboxyliques, leur préparation et médicaments les contenant.
AU671491B2 (en) 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
JPH0710876A (ja) * 1993-06-24 1995-01-13 Teijin Ltd ４位に環状アミノ基を有するピロロ［２，３―ｄ］ピリミジン
USH1439H (en) 1993-10-18 1995-05-02 The Dow Chemical Company Method to increase the level of α-glycol in liquid epoxy resin
EP0727217A3 (en) 1995-02-10 1997-01-15 Suntory Ltd Pharmaceutical and cosmetic compositions containing God-type ellagitannin as an active ingredient
IL117580A0 (en) 1995-03-29 1996-07-23 Merck & Co Inc Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them
US5856326A (en) * 1995-03-29 1999-01-05 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0836602B1 (en) 1995-07-05 2002-01-30 E.I. Du Pont De Nemours And Company Fungicidal pyrimidinones
MX9800215A (es) 1995-07-06 1998-03-31 Novartis Ag Pirrolopirimidas y procesos para su preparacion.
US5630943A (en) * 1995-11-30 1997-05-20 Merck Patent Gesellschaft Mit Beschrankter Haftung Discontinuous countercurrent chromatographic process and apparatus
GB9604361D0 (en) 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
JP2000504023A (ja) 1996-04-03 2000-04-04 メルク エンド カンパニー インコーポレーテッド 癌治療方法
WO1997038664A2 (en) 1996-04-18 1997-10-23 Merck & Co., Inc. A method of treating cancer
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
EP0934270A1 (en) 1996-05-30 1999-08-11 Merck & Co., Inc. A method of treating cancer
US6624138B1 (en) 2001-09-27 2003-09-23 Gp Medical Drug-loaded biological material chemically treated with genipin
JP2001524079A (ja) 1997-04-07 2001-11-27 メルク エンド カンパニー インコーポレーテッド ガンの治療方法
US6063284A (en) 1997-05-15 2000-05-16 Em Industries, Inc. Single column closed-loop recycling with periodic intra-profile injection
US6060038A (en) * 1997-05-15 2000-05-09 Merck & Co., Inc. Radiolabeled farnesyl-protein transferase inhibitors
CA2295620A1 (en) * 1997-08-11 1999-02-18 Boehringer Ingelheim Pharmaceuticals, Inc. 5,6-heteroaryl-dipyrido¬2,3-b:3',2'-f|azepines and their use in the prevention or treatment of hiv infection
US7153845B2 (en) 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6075056A (en) 1997-10-03 2000-06-13 Penederm, Inc. Antifungal/steroid topical compositions
SE9800729L (sv) 1998-03-06 1999-09-07 Scotia Lipidteknik Ab Ny topikal formulering I
US6025366A (en) 1998-04-02 2000-02-15 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
PL345906A1 (en) 1998-06-04 2002-01-14 Abbott Lab Cell adhesion-inhibiting antinflammatory compounds
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
EP1087970B1 (en) 1998-06-19 2004-04-28 Pfizer Products Inc. PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
ATE459616T1 (de) 1998-08-11 2010-03-15 Novartis Ag Isochinoline derivate mit angiogenesis-hemmender wirkung
JP2000119271A (ja) 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd １ｈ―イミダゾピリジン誘導体
EP1109534B1 (en) 1998-09-10 2003-02-12 Nycomed Danmark A/S Quick release pharmaceutical compositions of drug substances
FR2785196B1 (fr) * 1998-10-29 2000-12-15 Inst Francais Du Petrole Procede et dispositif de separation avec des zones chromatographiques a longueur variable
US6375839B1 (en) * 1998-10-29 2002-04-23 Institut Francais Du Petrole Process and device for separation with variable-length chromatographic zones
US6413419B1 (en) * 1998-10-29 2002-07-02 Institut Francais Du Petrole Process and device for separation with variable-length chromatographic
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
JP2002538121A (ja) 1999-03-03 2002-11-12 メルク エンド カムパニー インコーポレーテッド プレニルタンパク質トランスフェラーゼの阻害剤
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
US6217895B1 (en) * 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6239113B1 (en) * 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
WO2000063168A1 (en) 1999-04-16 2000-10-26 Coelacanth Chemical Corporation Synthesis of azetidine derivatives
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
DE60013464T2 (de) 1999-10-13 2005-09-15 Banyu Pharmaceutical Co., Ltd. Substituierte imidazolin-derivate
US7235258B1 (en) 1999-10-19 2007-06-26 Nps Pharmaceuticals, Inc. Sustained-release formulations for treating CNS-mediated disorders
EP1382339B1 (en) * 1999-12-10 2007-12-05 Pfizer Products Inc. Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives
EP1263759B1 (en) * 1999-12-24 2010-09-08 Aventis Pharma Limited Azaindoles
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
US7235551B2 (en) * 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
PT1142566E (pt) * 2000-04-07 2004-02-27 Medidom Lab Formulacao oftalmica topica na forma de uma solucao aquosa e uso de uma ciclosporina em associacao com acido hialuronico ou um de seus sais e com polisorbato 80
AU4878601A (en) 2000-04-20 2001-11-07 Mitsubishi Corporation Aromatic amide compounds
EP1278748B1 (en) * 2000-04-25 2011-03-23 ICOS Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta
US7498304B2 (en) * 2000-06-16 2009-03-03 Curis, Inc. Angiogenesis-modulating compositions and uses
AU2001275495B2 (en) 2000-06-16 2006-08-17 Curis, Inc. Angiogenesis-modulating compositions and uses
US6335342B1 (en) 2000-06-19 2002-01-01 Pharmacia & Upjohn S.P.A. Azaindole derivatives, process for their preparation, and their use as antitumor agents
US6930115B2 (en) 2000-06-23 2005-08-16 Mitsubishi Pharma Corporation Antitumor effect potentiators
CN100351253C (zh) * 2000-06-26 2007-11-28 辉瑞产品公司 作为免疫抑制剂的吡咯并[2,3－d]嘧啶化合物
CA2413330A1 (en) 2000-06-28 2002-01-03 Smithkline Beecham P.L.C. Wet milling process
WO2002016370A1 (fr) 2000-08-22 2002-02-28 Hokuriku Seiyaku Co., Ltd. Derives de 1h-imidazopyridine
MXPA03005001A (es) 2000-12-05 2003-09-05 Vertex Pharma Inhibidores de n- terminal c-jun cinasas (jnk) y otras proteinas cinasas.
GB0100622D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds V111
JP2004520347A (ja) 2001-01-15 2004-07-08 グラクソ　グループ　リミテッド Ｌｄｌ−受容体発現のインデューサーとしてのアリールピペリジンおよびピペラジン誘導体
CA2436487A1 (en) 2001-01-30 2002-08-08 Cytopia Pty Ltd. Methods of inhibiting kinases
WO2002092573A2 (en) 2001-05-16 2002-11-21 Vertex Pharmaceuticals Incorporated Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
GB0115393D0 (en) 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
EP1414443B1 (en) * 2001-08-01 2006-11-15 Merck & Co., Inc. BENZIMIDAZO 4,5-f|ISOQUINOLINONE DERIVATIVES
JP4456365B2 (ja) 2001-09-19 2010-04-28 アベンティス・ファーマ・ソシエテ・アノニム 化合物
US6429231B1 (en) 2001-09-24 2002-08-06 Bradley Pharmaceuticals, Inc. Compositions containing antimicrobials and urea for the treatment of dermatological disorders and methods for their use
WO2003037347A1 (en) 2001-10-30 2003-05-08 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
JP2003155285A (ja) 2001-11-19 2003-05-27 Toray Ind Inc 環状含窒素誘導体
EP1460059A4 (en) * 2001-11-30 2005-01-05 Teijin Ltd PROCESS FOR PRODUCING 5- (3-CYANOPHENYL) -3-FORMYLBENZOIC ACID COMPOUND
GT200200234A (es) 2001-12-06 2003-06-27 Compuestos cristalinos novedosos
US6995144B2 (en) * 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
MXPA04010225A (es) 2002-04-15 2005-07-05 Adams Lab Inc Liberacion sostenida de la combinacion de guaifenesina con farmacos.
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
WO2003091246A1 (en) * 2002-04-26 2003-11-06 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
WO2003092595A2 (en) 2002-05-02 2003-11-13 Merck & Co., Inc Tyrosine kinase inhibitors
CN1658836A (zh) * 2002-05-07 2005-08-24 控制传输系统公司 形成药物传递装置的方法
US7122550B2 (en) * 2002-05-23 2006-10-17 Cytopia Pty Ltd Protein kinase inhibitors
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
US7385018B2 (en) * 2002-06-26 2008-06-10 Idemitsu Kosan Co., Ltd. Hydrogenated copolymer, process for producing the same, and hot-melt adhesive composition containing the same
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0215844D0 (en) * 2002-07-09 2002-08-14 Novartis Ag Organic compounds
JPWO2004007472A1 (ja) 2002-07-10 2005-11-17 小野薬品工業株式会社 Ｃｃｒ４アンタゴニストおよびその医薬用途
JP2006502183A (ja) 2002-09-20 2006-01-19 アルコン，インコーポレイテッド ドライアイ障害の処置のためのサイトカイン合成インヒビターの使用
US20040204404A1 (en) * 2002-09-30 2004-10-14 Robert Zelle Human N-type calcium channel blockers
WO2004041814A1 (en) 2002-11-04 2004-05-21 Vertex Pharmaceuticals Incorporated Heteroaryl-pyramidine derivatives as jak inhibitors
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
CL2003002353A1 (es) 2002-11-15 2005-02-04 Vertex Pharma Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
US20040099204A1 (en) 2002-11-25 2004-05-27 Nestor John J. Sheet, page, line, position marker
JP2006509000A (ja) 2002-11-26 2006-03-16 ファイザー・プロダクツ・インク 移植片拒絶反応の処置の方法
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
UY28126A1 (es) * 2002-12-24 2004-06-30 Alcon Inc Uso de glucocorticoides selectivos para la superficie ocular en el tratamiento de la sequedad ocular
US7135493B2 (en) 2003-01-13 2006-11-14 Astellas Pharma Inc. HDAC inhibitor
US7167750B2 (en) 2003-02-03 2007-01-23 Enteromedics, Inc. Obesity treatment with electrically induced vagal down regulation
JP2006518381A (ja) * 2003-02-07 2006-08-10 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼのインヒビターとして有用なヘテロアリール置換ピロール
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
EP1615906A1 (en) 2003-04-03 2006-01-18 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
SE0301373D0 (sv) * 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
SE0301372D0 (sv) * 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
FR2857454B1 (fr) 2003-07-08 2006-08-11 Aventis Pasteur Dosage des acides techoiques des bacteries gram+
US20050043346A1 (en) * 2003-08-08 2005-02-24 Pharmacia Italia S.P.A. Pyridylpyrrole derivatives active as kinase inhibitors
CA2536954C (en) 2003-08-29 2012-11-27 Exelixis, Inc. C-kit modulators and methods of use
US8084457B2 (en) 2003-09-15 2011-12-27 Lead Discovery Center Gmbh Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
DK1679074T3 (da) * 2003-10-24 2011-03-21 Santen Pharmaceutical Co Ltd Terapeutisk middel til keratoconjunktive forstyrrelser
US7387793B2 (en) 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
JP2007512316A (ja) 2003-11-25 2007-05-17 ファイザー・プロダクツ・インク アテローム性動脈硬化症の治療方法
CN1893952A (zh) 2003-12-17 2007-01-10 辉瑞产品公司 用于治疗移植排斥的吡咯并[2,3－d]嘧啶化合物
ES2527118T3 (es) 2003-12-19 2015-01-20 Plexxikon Inc. Compuestos y procedimientos de desarrollo de moduladores de Ret
MXPA06007076A (es) * 2003-12-19 2006-08-31 Pharmacopeia Drug Discovery Tiadiazoles como ligandos del receptor cxc y cc-quimiocina.
JP4928949B2 (ja) 2003-12-23 2012-05-09 アステックス、セラピューティックス、リミテッド タンパク質キナーゼモジュレーターとしてのピラゾール誘導体
US20050165029A1 (en) * 2004-01-13 2005-07-28 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
US20050277629A1 (en) 2004-03-18 2005-12-15 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies (Lansbury)
EP1730146B1 (en) 2004-03-30 2011-05-04 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of jak and other protein kinases
EP1750727A2 (en) 2004-04-23 2007-02-14 Exelixis, Inc. Kinase modulators and methods of use
US7558717B2 (en) 2004-04-28 2009-07-07 Vertex Pharmaceuticals Incorporated Crystal structure of human JAK3 kinase domain complex and binding pockets thereof
WO2005105814A1 (en) * 2004-04-28 2005-11-10 Incyte Corporation Tetracyclic inhibitors of janus kinases
BRPI0510627A (pt) 2004-05-03 2007-10-30 Novartis Ag combinações que compreendem um agonista do receptor s1p e um inibidor da jak3 quinase
WO2005110410A2 (en) 2004-05-14 2005-11-24 Abbott Laboratories Kinase inhibitors as therapeutic agents
PE20060426A1 (es) 2004-06-02 2006-06-28 Schering Corp DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa
MXPA06014247A (es) 2004-06-10 2007-03-12 Irm Llc Compuestos y composiciones como inhibidores de la proteina quinasa.
EP1760071A4 (en) 2004-06-23 2008-03-05 Ono Pharmaceutical Co COMPOUND WITH S1P RECEPTOR BINDING ABILITY AND USE THEREOF
EP1765819B1 (en) 2004-06-30 2014-03-12 Vertex Pharmaceuticals Inc. Azaindoles useful as inhibitors of protein kinases
US7138423B2 (en) 2004-07-20 2006-11-21 Bristol-Myers Squibb Company Arylpyrrolidine derivatives as NK-1 /SSRI antagonists
FR2873691B1 (fr) 2004-07-29 2006-10-06 Sanofi Synthelabo Derives d'amino-piperidine, leur preparation et leur application en therapeutique
WO2006013114A1 (en) 2004-08-06 2006-02-09 Develogen Aktiengesellschaft Use of a timp-2 secreted protein product for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
WO2006022459A1 (en) 2004-08-23 2006-03-02 Mogam Biotechnology Institute Primer and probe for detection of sars coronavirus, kit comprising the primer and/or the probe, and detection method thereof
GB0421525D0 (en) 2004-09-28 2004-10-27 Novartis Ag Inhibitors of protein kineses
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
KR100858262B1 (ko) * 2004-10-13 2008-09-11 에프. 호프만-라 로슈 아게 Ｃｄｋ2 및 혈관신생에 대한 저해제로서 유용하고, 유방암,대장암, 폐암 및 전립선암의 치료용으로 유용한이중치환된 피라졸로벤조디아제핀
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
WO2006052913A1 (en) 2004-11-04 2006-05-18 Vertex Pharmaceuticals Incorporated PYRAZOLO[1,5-a]PYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES
RU2007123675A (ru) 2004-11-24 2008-12-27 Новартис АГ (CH) Комбинации ингибиторов jak
US7517870B2 (en) * 2004-12-03 2009-04-14 Fondazione Telethon Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
WO2006065916A1 (en) * 2004-12-14 2006-06-22 Alcon, Inc. Method of treating dry eye disorders using 13(s)-hode and its analogs
TW200635899A (en) 2004-12-22 2006-10-16 Astrazeneca Ab Chemical compounds
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
JP2008528477A (ja) 2005-01-20 2008-07-31 ファイザー・リミテッド 化合物
CN101142218B (zh) * 2005-02-03 2013-02-06 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的吡咯并嘧啶
WO2007044050A2 (en) 2005-02-04 2007-04-19 Bristol-Myers Squibb Company 1h-imidazo[4,5-d]thieno[3,2-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
US20080188483A1 (en) 2005-03-15 2008-08-07 Irm Llc Compounds and Compositions as Protein Kinase Inhibitors
EP1874772A1 (en) 2005-04-05 2008-01-09 Pharmacopeia, Inc. Purine and imidazopyridine derivatives for immunosuppression
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
ATE540948T1 (de) * 2005-05-20 2012-01-15 Vertex Pharma Pyrrolopyridine als proteinkinasehemmer
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
SG137989A1 (en) 2005-06-08 2008-01-28 Rigel Pharmaceuticals Inc Compositions and methods for inhibition of the JAK pathway
WO2006136823A1 (en) 2005-06-21 2006-12-28 Astex Therapeutics Limited Heterocyclic containing amines as kinase b inhibitors
CN102603581B (zh) 2005-06-22 2015-06-24 普莱希科公司 作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物
CN102127078A (zh) 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
FR2889662B1 (fr) 2005-08-11 2011-01-14 Galderma Res & Dev Emulsion de type huile-dans-eau pour application topique en dermatologie
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
EP2270014A1 (en) 2005-09-22 2011-01-05 Incyte Corporation Azepine inhibitors of janus kinases
US8580802B2 (en) 2005-09-30 2013-11-12 Vertex Pharmaceuticals Incorporated Pyrrolo[2,3-D]pyrimidines as inhibitors of Janus kinases
WO2007044894A2 (en) 2005-10-11 2007-04-19 Chembridge Research Laboratories, Inc. Cell-free protein expression systems and methods of use thereof
KR101315574B1 (ko) 2005-10-14 2013-10-08 스미또모 가가꾸 가부시끼가이샤 히드라지드 화합물 및 이의 살충 용도
RU2463302C2 (ru) 2005-10-28 2012-10-10 Астразенека Аб Производные 4-(3-аминопиразол)пиримидина для применения в качестве ингибиторов тирозинкиназы для лечения злокачественного новообразования
CN103626742B (zh) * 2005-11-01 2017-04-26 塔格根公司 激酶的联-芳基间-嘧啶抑制剂
WO2007062459A1 (en) 2005-11-29 2007-06-07 Cytopia Research Pty Ltd Selective kinase inhibitors based on pyridine scaffold
US20130137681A1 (en) 2005-12-13 2013-05-30 Incyte Corporation HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS
ES2612196T3 (es) * 2005-12-13 2017-05-12 Incyte Holdings Corporation Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas sustituidas con heteroarilo como inhibidores de quinasas Janus
WO2007076423A2 (en) 2005-12-22 2007-07-05 Smithkline Beecham Corporation INHIBITORS OF Akt ACTIVITY
SI1962830T1 (sl) * 2005-12-23 2013-07-31 Glaxosmithkline Llc Azaindolni inhibitorji kinaz Aurora
JP4643455B2 (ja) 2006-01-12 2011-03-02 株式会社ユニバーサルエンターテインメント 遊技システム
CA2636189A1 (en) 2006-01-17 2007-07-26 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of janus kinases
CA2635899A1 (en) * 2006-01-19 2007-07-26 Osi Pharmaceuticals, Inc. Fused heterobicyclic kinase inhibitors
WO2007090141A2 (en) 2006-02-01 2007-08-09 Smithkline Beecham Corporation Pyrrolo [2, 3, b] pyridine derivatives useful as raf kinase inhibitors
US7745477B2 (en) 2006-02-07 2010-06-29 Hoffman-La Roche Inc. Heteroaryl and benzyl amide compounds
PL1842534T3 (pl) 2006-02-24 2012-05-31 Teva Pharma Tabletki bursztynianu metoprololu o przedłużonym uwalnianiu oraz sposoby ich wytwarzania
CA2644368A1 (en) * 2006-03-10 2007-09-20 Ono Pharmaceutical Co., Ltd. Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
AU2007236707C1 (en) * 2006-04-03 2012-05-24 Astellas Pharma Inc. Hetero compound
EP2001884A1 (en) * 2006-04-05 2008-12-17 Vertex Pharmaceuticals, Inc. Deazapurines useful as inhibitors of janus kinases
CA2647448A1 (en) 2006-04-12 2007-10-18 Pfizer Limited Pyrrolidine derivatives as modulators of chemokine ccr5 receptors
WO2007129195A2 (en) 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds
US20080051427A1 (en) 2006-05-18 2008-02-28 Fritz Schuckler Pharmaceutical Compositions and Methods of Using Same
US7691811B2 (en) * 2006-05-25 2010-04-06 Bodor Nicholas S Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
TWI398252B (zh) 2006-05-26 2013-06-11 Novartis Ag 吡咯并嘧啶化合物及其用途
NZ573174A (en) 2006-06-01 2012-01-12 Msd Consumer Care Inc Sustained release pharmaceutical dosage form containing phenylephrine
WO2008011560A2 (en) * 2006-07-20 2008-01-24 Mehmet Kahraman Benzothiophene inhibitors of rho kinase
WO2008013622A2 (en) 2006-07-27 2008-01-31 E. I. Du Pont De Nemours And Company Fungicidal azocyclic amides
US8492378B2 (en) * 2006-08-03 2013-07-23 Takeda Pharmaceutical Company Limited GSK-3β inhibitor
JP5252404B2 (ja) * 2006-08-16 2013-07-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピラジン化合物、その使用及び調製方法
AR062677A1 (es) 2006-09-08 2008-11-26 Novartis Ag Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
WO2008035376A2 (en) 2006-09-19 2008-03-27 Council Of Scientific & Industrial Research A novel bio-erodible insert for ophthalmic applications and a process for the preparation thereof
US7919490B2 (en) 2006-10-04 2011-04-05 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
TW200837064A (en) * 2006-10-04 2008-09-16 Pharmacopeia Inc 8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression
US20120225057A1 (en) 2006-10-11 2012-09-06 Deciphera Pharmaceuticals, Llc Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases
JP5357763B2 (ja) * 2006-11-06 2013-12-04 トレロ ファーマシューティカルズ， インコーポレイテッド イミダゾ［１，２−ｂ］ピリダジン誘導体およびピラゾロ［１，５−ａ］ピリダジン誘導体およびプロテインキナーゼインヒビターとしてのこれらの使用
US20080119496A1 (en) * 2006-11-16 2008-05-22 Pharmacopeia Drug Discovery, Inc. 7-Substituted Purine Derivatives for Immunosuppression
SI3034075T1 (sl) 2006-11-22 2018-12-31 Incyte Holdings Corporation Imidazotriazini in imidazopirimidini kot inhibitorji kinaze
WO2008067119A2 (en) 2006-11-27 2008-06-05 Smithkline Beecham Corporation Novel compounds
CA2672616A1 (en) * 2006-12-15 2008-06-26 Abbott Laboratories Novel oxadiazole compounds
AU2007338793B2 (en) * 2006-12-20 2012-05-03 Amgen Inc. Heterocyclic compounds and their use in treating inflammation, angiogenesis and cancer
AU2007338792B2 (en) 2006-12-20 2012-05-31 Amgen Inc. Substituted heterocycles and methods of use
EP2121692B1 (en) 2006-12-22 2013-04-10 Incyte Corporation Substituted heterocycles as janus kinase inhibitors
BRPI0720434A2 (pt) 2006-12-22 2014-01-07 Sigma Tau Ind Farmaceuti Gel útil para liberação de fármacos oftálmicos
WO2008082839A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
KR20080062876A (ko) 2006-12-29 2008-07-03 주식회사 대웅제약 신규한 항진균성 트리아졸 유도체
WO2008082840A1 (en) 2006-12-29 2008-07-10 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
AU2008221263B2 (en) 2007-03-01 2012-02-23 Novartis Ag Pim kinase inhibitors and methods of their use
AU2008237507B2 (en) 2007-04-03 2014-03-20 Array Biopharma Inc. Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
US8188178B2 (en) 2007-05-07 2012-05-29 3M Innovative Properties Company Cold shrinkable article including an epichlorohydrin composition
GB0709031D0 (en) 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
EP2155689B1 (en) 2007-05-31 2015-07-08 Boehringer Ingelheim International GmbH Ccr2 receptor antagonists and uses thereof
GB0710528D0 (en) 2007-06-01 2007-07-11 Glaxo Group Ltd Novel compounds
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
MX342814B (es) 2007-06-13 2016-10-13 Incyte Holdings Corp Sales de inhibidor de janus cinasa (r)-3-(4-7h-pirrolo[2,3-d]pirim idin-4-il)-1h-pirazol-1-il)-3-ciclopentilpropanitrilo.
AU2008273804B2 (en) 2007-07-11 2014-07-10 Pfizer Inc. Pharmaceutical compositions and methods of treating dry eye disorders
AU2008281543A1 (en) 2007-08-01 2009-02-05 Pfizer Inc. Pyrazole compounds and their use as Raf inhibitors
WO2009049028A1 (en) 2007-10-09 2009-04-16 Targegen Inc. Pyrrolopyrimidine compounds and their use as janus kinase modulators
US20110263664A1 (en) 2007-11-15 2011-10-27 Musc Foundation For Research Development Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer
CN101910152B (zh) 2007-11-16 2014-08-06 因塞特公司 作为janus激酶抑制剂的4-吡唑基-n-芳基嘧啶-2-胺和4-吡唑基-n-杂芳基嘧啶-2-胺
GB0723815D0 (en) 2007-12-05 2008-01-16 Glaxo Group Ltd Compounds
PL3133080T3 (pl) * 2008-01-18 2018-12-31 Inst Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Nowe cytostatyczne nukleozydy 7-deazapurynowe
BRPI0905952A2 (pt) 2008-02-04 2015-06-30 Mercury Therapeutics Composto e sais do mesmo e compição farmacêutica
UY31679A1 (es) 2008-03-03 2009-09-30 Inhibidores de cinasa pim y metodos para su uso
MX2010010012A (es) 2008-03-11 2010-10-20 Incyte Corp Derivados de azetidina y ciclobutano como inhibidores de jak.
EA201001456A1 (ru) 2008-03-21 2011-06-30 Новартис Аг Новые гетероциклические соединения и их применение
CA2727928A1 (en) 2008-06-18 2009-12-23 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
US20110212157A1 (en) 2008-06-26 2011-09-01 Anterios, Inc. Dermal delivery
UY31952A (es) 2008-07-02 2010-01-29 Astrazeneca Ab 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
FR2933409B1 (fr) 2008-07-03 2010-08-27 Centre Nat Rech Scient NOUVEAUX PYRROLO °2,3-a! CARBAZOLES ET LEUR UTILISATION COMME INHIBITEURS DES KINASES PIM
WO2010022081A1 (en) 2008-08-19 2010-02-25 Array Biopharma Inc. Triazolopyridine compounds as pim kinase inhibitors
TWI496779B (zh) 2008-08-19 2015-08-21 Array Biopharma Inc 作為ｐｉｍ激酶抑制劑之三唑吡啶化合物
BRPI0917459B1 (pt) 2008-08-20 2017-09-12 Zoetis Services Llc N-methyl-1- [trans-4- [methyl (7h-pyrrol [2,3-d] pyridol [2,3-d] pyrimidine compounds, use of these in therapy and crystalline a form of n-methyl- pyrimidin-4-yl) amino] cyclohexyl} methanosulphonamide
WO2010026121A1 (en) 2008-09-02 2010-03-11 Novartis Ag Bicyclic kinase inhibitors
EP2344473B1 (en) 2008-09-02 2014-04-16 Novartis AG Heterocyclic pim-kinase inhibitors
PL2344474T3 (pl) 2008-09-02 2016-03-31 Novartis Ag Pochodne pikolinamidu jako inhibitory kinaz
CL2009001884A1 (es) 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
AU2009304508A1 (en) 2008-10-17 2010-04-22 Merck Frosst Canada Ltd. Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
JOP20190230A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
EP2210890A1 (en) 2009-01-19 2010-07-28 Almirall, S.A. Oxadiazole derivatives as S1P1 receptor agonists
US8263601B2 (en) 2009-02-27 2012-09-11 Concert Pharmaceuticals, Inc. Deuterium substituted xanthine derivatives
KR20120030447A (ko) 2009-05-22 2012-03-28 인사이트 코포레이션 Ｊａｋ 저해물질로서 ３-［４-（７ｈ-피롤로［２,３-ｄ］피리미딘-４-일）-１ｈ-피라졸-１-일］옥탄- 또는 헵탄-니트릴
CA2762174C (en) 2009-05-22 2018-02-20 Incyte Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
UA110324C2 (en) 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
WO2011003418A1 (en) 2009-07-08 2011-01-13 Leo Pharma A/S Heterocyclic compounds as jak receptor and protein tyrosine kinase inhibitors
WO2011025685A1 (en) 2009-08-24 2011-03-03 Merck Sharp & Dohme Corp. Jak inhibition blocks rna interference associated toxicities
TW201111385A (en) 2009-08-27 2011-04-01 Biocryst Pharm Inc Heterocyclic compounds as janus kinase inhibitors
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP2475659B1 (en) 2009-09-08 2015-10-28 F.Hoffmann-La Roche Ag 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
EP2305660A1 (en) 2009-09-25 2011-04-06 Almirall, S.A. New thiadiazole derivatives
EA021478B1 (ru) 2009-10-09 2015-06-30 Инсайт Корпорейшн ГИДРОКСИЛЬНЫЕ, КЕТО И ГЛЮКУРОНИДНЫЕ ПРОИЗВОДНЫЕ 3-(4-(7Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1Н-ПИРАЗОЛ-1-ИЛ)-3-ЦИКЛОПЕНТИЛПРОПАННИТРИЛА
KR20120102601A (ko) 2009-10-20 2012-09-18 셀좀 리미티드 Ｊａｋ 저해제로서의 헤테로시클릴 피라졸로피리미딘 유사체
US20110113416A1 (en) 2009-11-09 2011-05-12 Bank Of America Corporation Network-Enhanced Control Of Software Updates Received Via Removable Computer-Readable Medium
EP2332917B1 (en) 2009-11-11 2012-08-01 Sygnis Bioscience GmbH & Co. KG Compounds for PIM kinase inhibition and for treating malignancy
CN102740888B (zh) 2009-11-24 2016-10-12 奥尔德生物制药公司 Il-6抗体及其用途
WO2011069141A2 (en) 2009-12-04 2011-06-09 Board Of Regents, The University Of Texas System Interferon therapies in combination with blockade of stat3 activation
ES2461967T3 (es) 2009-12-18 2014-05-21 Pfizer Inc. Compuestos de pirrolo[2,3-d]pirimidina
AR079984A1 (es) 2010-01-12 2012-03-07 Hoffmann La Roche Compuestos heterociclicos triciclicos, composiciones y su uso en el tratamiento de enfermedades mediadas por la inhibicion de jak1
AU2011213198B2 (en) 2010-02-05 2014-04-24 Zoetis Llc Pyrrolo [ 2,3-d] pyrimidine urea compounds as JAK inhibitors
SA111320200B1 (ar) 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
WO2011103423A1 (en) * 2010-02-18 2011-08-25 Incyte Corporation Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
RS60680B1 (sr) 2010-03-10 2020-09-30 Incyte Holdings Corp Piperidin-4-il azetidin derivati kao inhibitori jak1
WO2011130146A1 (en) 2010-04-14 2011-10-20 Array Biopharma Inc. 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases
EP2390252A1 (en) 2010-05-19 2011-11-30 Almirall, S.A. New pyrazole derivatives
SG10201503983QA (en) 2010-05-21 2015-06-29 Incyte Corp Topical Formulation for a JAK Inhibitor
US8637529B2 (en) 2010-06-11 2014-01-28 AbbYie Inc. Pyrazolo[3,4-d]pyrimidine compounds
US9351943B2 (en) 2010-07-01 2016-05-31 Matthew T. McLeay Anti-fibroblastic fluorochemical emulsion therapies
WO2012045020A1 (en) 2010-09-30 2012-04-05 Portola Pharmaceuticals, Inc. Combinations of 4-(cyclopropylamino)-2-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenylamino)pyrimidine-5-carboxamide and fludarabine
TW201249845A (en) 2010-11-19 2012-12-16 Incyte Corp Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
EP2640725B1 (en) * 2010-11-19 2015-01-07 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
WO2012071612A1 (en) 2010-12-03 2012-06-07 Ym Biosciences Australia Pty Ltd Treatment of jak2-mediated conditions
MX357939B (es) * 2011-02-18 2018-07-31 Novartis Pharma Ag Terapia de combinacion de inhibidor de objetivo de rapamicina en mamifero/janus cinasa (mtor/jak).
CN102247368B (zh) 2011-05-19 2013-05-29 安徽永生堂药业有限责任公司 一种复方阿伐斯汀缓释片及其制备方法
CN102218042A (zh) 2011-05-26 2011-10-19 青岛黄海制药有限责任公司 富马酸喹硫平组合物的缓释片剂及其制备方法
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
WO2013007765A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
WO2013007768A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
WO2013023119A1 (en) 2011-08-10 2013-02-14 Novartis Pharma Ag JAK P13K/mTOR COMBINATION THERAPY
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
AR091079A1 (es) 2012-05-18 2014-12-30 Incyte Corp Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak
US10155987B2 (en) 2012-06-12 2018-12-18 Dana-Farber Cancer Institute, Inc. Methods of predicting resistance to JAK inhibitor therapy
IN2014DN10670A (hr) 2012-06-15 2015-08-28 Concert Pharmaceuticals Inc
CA2879603A1 (en) 2012-07-27 2014-01-30 Ratiopharm Gmbh Oral dosage forms for modified release comprising ruxolitinib
CN102772384A (zh) 2012-08-07 2012-11-14 四川百利药业有限责任公司 一种盐酸米诺环素缓释片及其制备方法
WO2014036016A1 (en) 2012-08-31 2014-03-06 Principia Biopharma Inc. Benzimidazole derivatives as itk inhibitors
US9181271B2 (en) 2012-11-01 2015-11-10 Incyte Holdings Corporation Tricyclic fused thiophene derivatives as JAK inhibitors
RS62329B1 (sr) 2012-11-15 2021-10-29 Incyte Holdings Corp Dozni oblici ruksolitiniba sa produženim vremenom oslobađanja
ES2900492T3 (es) 2013-03-06 2022-03-17 Incyte Holdings Corp Procesos y productos intermedios para elaborar un inhibidor de JAK
PT3231801T (pt) 2013-05-17 2019-05-24 Incyte Corp Sal de bipirazole como inibidor da jak
EA201690357A1 (ru) 2013-08-07 2016-07-29 Инсайт Корпорейшн Лекарственные формы с замедленным высвобождением для ингибитора jak1
AU2014309017A1 (en) 2013-08-20 2016-03-10 Incyte Corporation Survival benefit in patients with solid tumors with elevated C-reactive protein levels
PT3110409T (pt) 2014-02-28 2018-11-07 Incyte Corp Inibidores de jak1 para o tratamento de síndromes mielodisplásicas
CA2945151C (en) 2014-04-08 2022-08-02 Incyte Corporation Treatment of b-cell malignancies by a combination jak and pi3k inhibitors
EP3137471A1 (en) 2014-04-30 2017-03-08 Incyte Corporation Processes of preparing a jak1 inhibitor and new forms thereto
EP4233870A3 (en) 2014-05-28 2024-01-24 Onco Tracker, Inc. Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US10766900B2 (en) 2017-12-29 2020-09-08 Formosa Laboratories, Inc. Baricitinib intermediate, method for forming Baricitinib intermediate, and method for preparing Baricitinib or pharmaceutically acceptable salt thereof
WO2020163653A1 (en) 2019-02-06 2020-08-13 Concert Pharmaceuticals, Inc. Process for preparing enantiomerically enriched jak inhibitors

Also Published As

Publication number Publication date
US20100022522A1 (en) 2010-01-28
IL231992A (en) 2016-11-30
TW200728275A (en) 2007-08-01
SG10202003901UA (en) 2020-05-28
PL2348023T3 (pl) 2015-11-30
US8530485B2 (en) 2013-09-10
KR101216055B1 (ko) 2012-12-27
ES2543904T3 (es) 2015-08-25
SI2348023T1 (sl) 2015-10-30
KR20110137406A (ko) 2011-12-22
JP2011252024A (ja) 2011-12-15
EP2343299B1 (en) 2015-11-04
AR057995A1 (es) 2008-01-09
EP3184526A1 (en) 2017-06-28
ES2611588T3 (es) 2017-05-09
IL248938A0 (en) 2017-01-31
SG10201506912RA (en) 2015-10-29
KR20120120462A (ko) 2012-11-01
US10398699B2 (en) 2019-09-03
US11331320B2 (en) 2022-05-17
KR101324737B1 (ko) 2013-11-05
PT3184526T (pt) 2018-12-19
UA98449C2 (en) 2012-05-25
US20160272648A1 (en) 2016-09-22
US20200338077A1 (en) 2020-10-29
CA2632466A1 (en) 2007-06-21
SI2474545T1 (sl) 2017-03-31
EP2343299B9 (en) 2017-03-08
TWI553008B (zh) 2016-10-11
RS54683B1 (en) 2016-08-31
RS55576B1 (sr) 2017-05-31
HUE030235T2 (en) 2017-04-28
US8933086B2 (en) 2015-01-13
PT1966202E (pt) 2012-01-03
PT2343299E (pt) 2016-02-26
HUE032337T2 (en) 2017-09-28
PT2348023E (pt) 2015-09-15
KR101218214B1 (ko) 2013-01-04
US20110224157A1 (en) 2011-09-15
EP2343298A1 (en) 2011-07-13
EP3838903B1 (en) 2023-11-22
HRP20170200T1 (hr) 2017-04-07
LT2426129T (lt) 2017-02-10
BRPI0619817B8 (pt) 2021-05-25
CN103254190B (zh) 2016-12-07
EP1966202B1 (en) 2011-09-21
UA116187C2 (uk) 2018-02-26
EP2455382B1 (en) 2016-10-26
EP2455382A1 (en) 2012-05-23
EP2348023A1 (en) 2011-07-27
MY159449A (en) 2017-01-13
BRPI0619817A2 (pt) 2011-11-22
CN103214483A (zh) 2013-07-24
HK1171023A1 (zh) 2013-03-15
ATE525374T1 (de) 2011-10-15
CR20130506A (es) 2013-10-30
EP3184526B1 (en) 2018-10-03
DK2455382T3 (da) 2017-01-02
CY2013006I1 (el) 2015-10-07
EA201200132A8 (ru) 2018-10-31
EP2343298B1 (en) 2015-05-06
ES2612489T3 (es) 2017-05-17
ES2612196T3 (es) 2017-05-12
CN103214484A (zh) 2013-07-24
TWI664182B (zh) 2019-07-01
CY2017015I2 (el) 2017-09-13
EA201200132A1 (ru) 2017-01-30
AU2006326548B2 (en) 2012-04-05
US20220395506A1 (en) 2022-12-15
HRP20160112T1 (hr) 2016-02-26
HUE030418T2 (en) 2017-05-29
CR10065A (es) 2008-07-10
TW201831490A (zh) 2018-09-01
NZ569015A (en) 2011-06-30
EA200870048A1 (ru) 2009-02-27
KR20080079677A (ko) 2008-09-01
CY1118506T1 (el) 2017-07-12
LT2474545T (lt) 2017-02-27
MX346183B (es) 2017-03-10
TW201434835A (zh) 2014-09-16
US9079912B2 (en) 2015-07-14
US11744832B2 (en) 2023-09-05
US20150238492A1 (en) 2015-08-27
US20140005210A1 (en) 2014-01-02
SG179430A1 (en) 2012-04-27
US9974790B2 (en) 2018-05-22
EP3466953B1 (en) 2021-02-03
HK1160115A1 (zh) 2012-08-10
CY1118724T1 (el) 2017-07-12
HRP20110903T1 (hr) 2012-01-31
PL2426129T3 (pl) 2017-04-28
JP2009519340A (ja) 2009-05-14
MY162590A (en) 2017-06-30
LT2455382T (lt) 2017-02-10
CY2017015I1 (el) 2017-09-13
EP1966202A1 (en) 2008-09-10
PL2343299T3 (pl) 2016-09-30
FR17C1013I1 (fr) 2017-06-02
ZA200805165B (en) 2012-05-30
EP2474545A1 (en) 2012-07-11
PL2474545T3 (pl) 2017-04-28
DK2348023T5 (da) 2017-05-15
TWI630207B (zh) 2018-07-21
SI2455382T1 (sl) 2017-03-31
BRPI0619817A8 (pt) 2018-01-23
US20190125750A1 (en) 2019-05-02
PT2474545T (pt) 2017-02-14
US7598257B2 (en) 2009-10-06
CY1116574T1 (el) 2018-03-07
JP2014051531A (ja) 2014-03-20
JP6138865B2 (ja) 2017-05-31
HUS1700017I1 (hu) 2017-05-29
ECSP088540A (es) 2008-07-30
HUE025173T2 (hu) 2016-01-28
US8415362B2 (en) 2013-04-09
DK3184526T3 (en) 2019-01-14
HRP20150837T2 (hr) 2017-04-07
TW201522344A (zh) 2015-06-16
DK2426129T3 (en) 2017-01-16
CN103214483B (zh) 2014-12-17
ES2970354T3 (es) 2024-05-28
US9814722B2 (en) 2017-11-14
RS55634B1 (sr) 2017-06-30
CY1121202T1 (el) 2020-05-29
DK2474545T3 (en) 2017-01-23
HK1160111A1 (en) 2012-08-10
ES2543903T3 (es) 2015-08-25
HUE041382T2 (hu) 2019-05-28
EA201691294A2 (ru) 2018-11-30
EP3838903A1 (en) 2021-06-23
ES2561507T3 (es) 2016-02-26
US10639310B2 (en) 2020-05-05
IL192019A0 (en) 2008-12-29
HRP20170090T1 (hr) 2017-03-24
JP2015193641A (ja) 2015-11-05
LU92137I2 (fr) 2014-01-18
JP5876026B2 (ja) 2016-03-02
SI2426129T1 (sl) 2017-02-28
EP2426129A1 (en) 2012-03-07
PT2455382T (pt) 2017-01-31
KR20120120463A (ko) 2012-11-01
EA036785B1 (ru) 2020-12-21
BRPI0619817B1 (pt) 2020-03-17
SI1966202T1 (sl) 2012-01-31
TW201704235A (zh) 2017-02-01
US20180338978A1 (en) 2018-11-29
KR101391900B1 (ko) 2014-05-02
EP2474545B1 (en) 2016-11-09
PL3184526T3 (pl) 2019-04-30
ES2867505T3 (es) 2021-10-20
RS54181B1 (en) 2015-12-31
DK1966202T3 (da) 2012-01-16
RS58113B1 (sr) 2019-02-28
HRP20170162T1 (hr) 2017-03-24
WO2007070514A1 (en) 2007-06-21
LT3184526T (lt) 2019-02-25
HRP20181912T1 (hr) 2019-03-22
US20110223210A1 (en) 2011-09-15
CN101448826A (zh) 2009-06-03
ECSP12008540A (es) 2012-04-30
PL2455382T3 (pl) 2017-04-28
CN103254190A (zh) 2013-08-21
EA019504B1 (ru) 2014-04-30
DK2348023T3 (da) 2015-06-22
HK1124840A1 (en) 2009-07-24
RS55632B1 (sr) 2017-06-30
EP2348023B9 (en) 2017-03-08
RS54181B9 (sr) 2020-01-31
RS52101B (en) 2012-06-30
EP2343298B9 (en) 2020-05-06
EP2348023B1 (en) 2015-05-06
NZ778831A (en) 2022-12-23
US8541425B2 (en) 2013-09-24
PL1966202T3 (pl) 2012-02-29
US9206187B2 (en) 2015-12-08
US20160346286A1 (en) 2016-12-01
US20170071947A1 (en) 2017-03-16
IL192019A (en) 2014-04-30
AU2006326548A1 (en) 2007-06-21
IL231992A0 (en) 2014-05-28
SI3184526T1 (sl) 2019-03-29
JP5710430B2 (ja) 2015-04-30
US20090181959A1 (en) 2009-07-16
TWI410407B (zh) 2013-10-01
LTPA2017012I1 (lt) 2017-05-10
US20140018374A1 (en) 2014-01-16
EP2426129B1 (en) 2016-11-02
EP3466953A1 (en) 2019-04-10
US8946245B2 (en) 2015-02-03
US20070135461A1 (en) 2007-06-14
EP2343299A1 (en) 2011-07-13
SI2343299T1 (sl) 2016-06-30
HK1160137A1 (en) 2012-08-10
CY1112762T1 (el) 2015-10-07
ME01312B (me) 2013-12-20
CY2013006I2 (el) 2015-10-07
EA035795B1 (ru) 2020-08-11
ES2373688T3 (es) 2012-02-07
HUE028588T2 (hu) 2016-12-28
TW201240663A (en) 2012-10-16
ES2700433T3 (es) 2019-02-15
JP5017278B2 (ja) 2012-09-05
TWI468162B (zh) 2015-01-11
CN103214484B (zh) 2016-07-06
CY1118607T1 (el) 2017-07-12
US9662335B2 (en) 2017-05-30
LU92137I9 (hr) 2019-01-04
CA2632466C (en) 2013-09-24
FR17C1013I2 (fr) 2018-05-04
DK2343299T3 (en) 2016-01-18
US20140243360A1 (en) 2014-08-28
ES2543904T9 (es) 2017-05-29
PT2426129T (pt) 2017-02-10

Similar Documents

Publication Publication Date Title
HRP20150837T1 (hr) Heteroaril supstituirani pirolo[2,3-b]piridini i pirolo[2,3-b]pirimidini kao inhibitori janus kinaze
JP2011252024A5 (hr)
HRP20231614T1 (hr) Spojevi pirolotriazina kao tam inhibitori
JP2022184886A5 (hr)
JP2005500315A5 (hr)
JP2004527560A5 (hr)
HRP20181014T1 (hr) Pirazoli derivati modulatori kalcijevih kanala aktiviranih oslobađanjem kalcija i metode za liječenje nesitnostaničnog karcinoma pluća
JP2017052805A5 (hr)
RU2469032C2 (ru) Производные 2-(пиперидин-4-ил)-4-фенокси- или фениламинопиримидина в качестве ненуклеозидных ингибиторов обратной транскриптазы
JP2013523889A5 (hr)
JP2004528312A5 (hr)
JP2004529926A5 (hr)
JP2019535664A5 (hr)
RU2012132426A (ru) ПРОИЗВОДНЫЕ ТИЕНО[3,2-d]ПИРИМИДИНА, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ ПРОТЕИНКИНАЗЫ
HRP20140309T1 (hr) SUPSTITUIRANI SPOJEVI PIRAZOLO[1,5-a]PIRIMIDINA KAO INHIBITORI TRK KINAZE
JP2010529208A5 (hr)
JP2016538316A5 (hr)
JP2016523923A5 (hr)
JP2010510319A5 (hr)
AR073010A1 (es) Compuesto amida con actividad agonista del gpr52
JP2019529443A5 (hr)
HRP20212000T1 (hr) Aminotriazolopiridini kao inhibitori kinaze
RU2007101501A (ru) Аридзамещенные пиперазиновые производные
RU2006121337A (ru) Производные пиразола и их применение в качестве ингибиторов рецепторных тирозинкиназ
JP2009532438A5 (hr)